[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 212
1. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. Neurology; 2009 Nov 17;73(20):1677-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent ependymoma.
  • BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies.
  • At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor.
  • METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):211-6 [15614581.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):159-67 [19019565.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • (PMID = 19917990.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA-105663-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2788805
  •  go-up   go-down


2. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Birks DK, Handler MH, Foreman NK: Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol; 2010 May;20(3):560-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique molecular characteristics of pediatric myxopapillary ependymoma.
  • Myxopapillary ependymoma (MEPN) generally can be cured by gross total surgical resection and usually manifest a favorable prognosis.
  • Unique molecular features of MEPN were investigated by using microarray technology to compare the gene expression of five pediatric MEPN to 24 pediatric intracranial ependymoma (EPN).
  • The upregulation of three genes of interest, homeobox B13 (HOXB13), neurofilament, light polypeptide (NEFL) and PDGFR alpha, was further studied by immunohistochemistry in a larger cohort that included adult MEPN and EPN specimens.
  • Protein expression in MEPN was compared to subependymoma, spinal EPN, intracranial EPN and normal fetal and adult ependyma.
  • [MeSH-major] Ependymoma / genetics. Ependymoma / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):30-6 [10765136.001]
  • [Cites] Cancer. 2009 Sep 1;115(17):3955-68 [19536879.001]
  • [Cites] Med Pediatr Oncol. 2000 Oct;35(4):443-5 [11025481.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):162-9 [11813208.001]
  • [Cites] Leukemia. 2002 Feb;16(2):186-95 [11840284.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Exp Cell Res. 2004 Feb 1;293(1):144-53 [14729064.001]
  • [Cites] Acta Neurochir (Wien). 2004 Nov;146(11):1255-8 [15365794.001]
  • [Cites] J Surg Oncol. 1983 Jan;22(1):33-6 [6823114.001]
  • [Cites] Cell. 1984 Oct;38(3):667-73 [6091895.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):31-6 [2909684.001]
  • [Cites] Nucleic Acids Res. 1989 Dec 25;17(24):10385-402 [2574852.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):237-44 [7678830.001]
  • [Cites] Childs Nerv Syst. 1993 Feb;9(1):3-6 [8481942.001]
  • [Cites] Acta Neurochir (Wien). 1993;124(2-4):99-103 [8304078.001]
  • [Cites] Pediatr Neurosurg. 1998 May;28(5):273-8 [9732262.001]
  • [Cites] Pediatr Neurosurg. 1998 Jun;28(6):314-9 [9782208.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3045-50 [9865919.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Leukemia. 1999 May;13(5):687-98 [10374871.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):25-8 [15803371.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):59-64 [16206735.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] J Neurooncol. 2007 May;83(1):85-9 [17206474.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5806-13 [17575148.001]
  • [Cites] Dev Dyn. 2007 Sep;236(9):2454-63 [17685480.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):990-8 [19093257.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):470-5 [19156136.001]
  • [Cites] Expert Opin Ther Targets. 2009 Apr;13(4):443-54 [19335066.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):321-34; discussion 334 [19221818.001]
  • [Cites] Nature. 2000 Jun 22;405(6789):974-8 [10879542.001]
  • (PMID = 19793339.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2871180
  •  go-up   go-down


3. Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C: Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer; 2007;6:47
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma.
  • Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors.
  • We define a newly recognized subset of ependymal tumors, the trisomy 19 ependymoma.
  • When containing clear cells they are called clear cell ependymoma.
  • These altered chromosomal regions are indicative of genes and pathways involved in trisomy 19 ependymoma tumorigenesis.
  • [MeSH-major] Brain Neoplasms / pathology. Chromosomes, Human, Pair 19 / genetics. Ependymoma / pathology. Trisomy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 9 / genetics. Female. Genome, Human. Humans. Infant. Male. Microsatellite Repeats / genetics. Middle Aged. Nucleic Acid Hybridization / methods. Polymorphism, Single Nucleotide. Tissue Array Analysis / methods. Tissue Fixation / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):141-52 [12790776.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):820-6 [9236838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11268-73 [9326598.001]
  • [Cites] Surg Neurol. 1999 Mar;51(3):281-7; discussion 287-8 [10086492.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):361-8 [15781323.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3542-7 [15867346.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Oct;29(5):462-71 [14507338.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2232-44 [14601094.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Dec;29(6):574-83 [14636164.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):9-14 [14631364.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):24-30 [15108012.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9527-41 [15485920.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(5):467-72 [2477945.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):7953-65 [16135788.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1216-21 [16357509.001]
  • [Cites] Genomics. 2006 Feb;87(2):298-306 [16271290.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6664-72 [16317011.001]
  • [Cites] Calcif Tissue Int. 2006 Apr;78(4):233-40 [16604287.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):268-76 [16645215.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):14711-8 [16595680.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):391-400 [16764692.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):958-62 [16648869.001]
  • [Cites] Lab Invest. 2006 Sep;86(9):968-78 [16751780.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1137-43 [11238062.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46460-8 [11585837.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1109-19 [11106750.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):929-39 [11953826.001]
  • [Cites] Mod Pathol. 2002 May;15(5):526-31 [12011257.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • (PMID = 17626628.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950527
  •  go-up   go-down


Advertisement
4. Higgins GS, Smith C, Summers DM, Statham PX, Erridge SC: Myxopapillary ependymoma with intracranial metastases. Br J Neurosurg; 2005 Aug;19(4):356-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxopapillary ependymoma with intracranial metastases.
  • We report spontaneous seeding within the subarachnoid space from a myxopapillary ependymoma that progressed despite surgery and radiotherapy treatment.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / secondary. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Lumbar Vertebrae. Magnetic Resonance Imaging. Subarachnoid Space. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Neurosurg. 2006 Apr;20(2):114 [16753632.001]
  • (PMID = 16455546.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Sarikaya S, Acikgöz B, Tekkök IH, Güngen YY: Conus ependymoma with holocord syringohydromyelia and syringobulbia. J Clin Neurosci; 2007 Sep;14(9):901-4
MedlinePlus Health Information. consumer health - Syringomyelia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conus ependymoma with holocord syringohydromyelia and syringobulbia.
  • We report a 24-year-old woman with an intramedullary conus ependymoma associated with holocord syringohydromyelia and syringobulbia.
  • [MeSH-major] Brain Stem Neoplasms / complications. Ependymoma / complications. Spinal Neoplasms / complications. Syringomyelia / complications
  • [MeSH-minor] Adult. Decompression, Surgical / methods. Female. Humans. Magnetic Resonance Imaging / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Syringobulbia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660060.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


6. Morris EB, Li C, Khan RB, Sanford RA, Boop F, Pinlac R, Xiong X, Merchant TE: Evolution of neurological impairment in pediatric infratentorial ependymoma patients. J Neurooncol; 2009 Sep;94(3):391-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of neurological impairment in pediatric infratentorial ependymoma patients.
  • BACKGROUND: Infratentorial ependymoma is a common central nervous system tumor of childhood and in patients >1 year of age is treated with maximally feasible surgical resection and radiotherapy.
  • PURPOSE: To characterize the incidence, evolution, and persistence of neurologic impairment in children with infratentorial ependymoma following maximal safe surgery and conformal or intensity-modulated radiation therapy (CRT/IMRT).
  • PATIENTS AND METHODS: After surgical resection, 96 children with non-metastatic infratentorial ependymoma were enrolled on a phase II study of image-guided radiation therapy and were prospectively followed with interval comprehensive neurological examinations.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):892-9 [18395355.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Mar;20(2):89-101 [12554520.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1347-51 [12663725.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1149-51 [1253128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):727-36 [7287533.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):304-10 [2355890.001]
  • [Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):781-7 [7960979.001]
  • [Cites] J Child Neurol. 1995 May;10(3):209-12 [7642890.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7143-51 [16192598.001]
  • [Cites] Contemp Clin Trials. 2006 Jun;27(3):269-73 [16388989.001]
  • [Cites] J Ky Med Assoc. 1999 Oct;97(10):465-71 [10544553.001]
  • (PMID = 19330288.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / P30 CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS105709; NLM/ PMC2731005
  •  go-up   go-down


7. Andrade FG, de Aguiar PH, Matushita H, Taricco MA, Oba-Shinjo SM, Marie SK, Teixeira MJ: Intracranial and spinal ependymoma: series at Faculdade de Medicina, Universidade de São Paulo. Arq Neuropsiquiatr; 2009 Sep;67(3A):626-32
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial and spinal ependymoma: series at Faculdade de Medicina, Universidade de São Paulo.
  • METHOD: Data of clinical presentation, tumor location, duration of symptoms, degree of resection and complementary treatment of 34 patients with intracranial ependymoma and 31 with intramedullary ependymoma who underwent surgery in the last ten years were collected and correlated with the recurrence time and overall survival.
  • Data analyses of intramedullary ependymoma did not show correlation with overall survival and likelihood of recurrence.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Hospitals, University. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722039.001).
  • [ISSN] 1678-4227
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


8. Gavin Quigley D, Farooqi N, Pigott TJ, Findlay GF, Pillay R, Buxton N, Jenkinson MD: Outcome predictors in the management of spinal cord ependymoma. Eur Spine J; 2007 Mar;16(3):399-404
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome predictors in the management of spinal cord ependymoma.
  • Twenty-six patients who underwent treatment of spinal cord ependymoma at a single institution were retrospectively analysed.
  • Extent of resection and the use of adjuvant radiotherapy did not influence PFS or OS; however, early diagnosis and treatment are paramount in the management of spinal ependymoma if a good functional outcome is to be achieved.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Spinal Cord Neoplasms / radiotherapy. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Data Interpretation, Statistical. Disease-Free Survival. Humans. Middle Aged. Predictive Value of Tests. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spinal Cord. 1999 Nov;37(11):753-9 [10578245.001]
  • [Cites] J Neurosurg. 1954 Nov;11(6):616-21 [13222169.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):997-1002 [12209682.001]
  • [Cites] Neurosurgery. 2002 Nov;51(5):1162-72; discussion 1172-4 [12383361.001]
  • [Cites] Paraplegia. 1969 Nov;7(3):179-92 [5360915.001]
  • [Cites] Brain. 1972;95(1):109-22 [5023080.001]
  • [Cites] Cancer. 1975 Jun;35(6):1558-62 [1148990.001]
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] Radiology. 1980 May;135(2):473-9 [7367644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):37-43 [7061255.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Jul;9(7):1093-6 [6863076.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):883-93 [4016681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1933-9 [2997089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):323-7 [3082807.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):855-9 [2601814.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):204-9 [8331401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):223-9 [8407395.001]
  • [Cites] Surg Neurol. 1996 Oct;46(4):322-8 [8876712.001]
  • [Cites] J Neurooncol. 2002 Apr;57(2):133-9 [12125974.001]
  • (PMID = 16865377.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2200709
  •  go-up   go-down


9. Miyazawa T, Hirose T, Nakanishi K, Uozumi Y, Tsuzuki N, Shima K: Supratentorial ectopic cortical ependymoma occurring with intratumoral hemorrhage. Brain Tumor Pathol; 2007;24(1):35-40
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial ectopic cortical ependymoma occurring with intratumoral hemorrhage.
  • We report here a rare case of supratentorial ectopic cortical ependymoma.
  • A cortical ependymoma should be considered in the differential diagnosis of supratentorial cortical tumors with intraparenchymal hemorrhage and high vascularity, even if not in contact with the ventricular system.
  • Although malignant transformation is unusual in cortical ependymoma, close observation and adjunctive radiotherapy are strongly recommended after the excision.
  • [MeSH-major] Ependymoma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Hemorrhage / etiology. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095143.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N: Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg; 2005 Jul;103(1):31-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome in patients harboring intracranial ependymoma.
  • OBJECT: The prognostic significance of tumor grade and resection and the efficacy of prophylactic radiation remain controversial in the management of intracranial ependymoma.
  • The outcomes in patients with intracranial ependymoma treated at the Kyoto University Hospital were reviewed retrospectively, and prognostic significance was analyzed.
  • Eighteen cases involved a Grade II lesion according to the World Health Organization classification of ependymoma and 11 involved a Grade III lesion.
  • Overall survival and progression-free survival rates were significantly higher in patients with Grade II ependymoma (p = 0.006 and 0.004, respectively) and in patients who had undergone gross-total resection of the tumor (p = 0.002 and 0.04, respectively).
  • In nine patients the ependymoma recurred only at the original tumor site.
  • All relapses of the Grade II ependymoma initially occurred at the primary tumor site.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Ependymoma / mortality. Ependymoma / therapy. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2006 Sep;105(3):503; author reply 503-4 [16961153.001]
  • [CommentIn] J Neurosurg. 2005 Jul;103(1):4; discussion 4-5 [16121965.001]
  • (PMID = 16121970.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Massimino M, Buttarelli FR, Antonelli M, Gandola L, Modena P, Giangaspero F: Intracranial ependymoma: factors affecting outcome. Future Oncol; 2009 Mar;5(2):207-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial ependymoma: factors affecting outcome.
  • The management of intracranial ependymoma is still not optimal.
  • The 5-year progression-free survival for children with ependymoma ranges between 30 and 50% with a worse prognosis for patients with residual disease after surgery.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Adult. Biomarkers / analysis. Child. Humans. Prognosis

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284379.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 68
  •  go-up   go-down


12. Roncaroli F, Consales A, Fioravanti A, Cenacchi G: Supratentorial cortical ependymoma: report of three cases. Neurosurgery; 2005 Jul;57(1):E192; discussion E192
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial cortical ependymoma: report of three cases.
  • Here, we report three patients with supratentorial intracortical ependymoma.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Neurosurgery / methods. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Microscopy, Electron, Transmission / methods. Middle Aged. Radiotherapy / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987557.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD: Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery; 2009 Feb;64(2):279-87; discussion 287-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome predictors for intracranial ependymoma radiosurgery.
  • METHODS: We retrospectively reviewed records of 39 consecutive ependymoma patients who underwent SRS for 56 tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / surgery. Ependymoma / epidemiology. Ependymoma / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Outcome Assessment (Health Care) / methods. Radiosurgery / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Pennsylvania / epidemiology. Retrospective Studies. Risk Assessment / methods. Risk Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190457.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Moreno L, Bautista FJ, Zacharoulis S: Outcome of teenagers and young adults with ependymoma: the Royal Marsden experience. Childs Nerv Syst; 2009 Sep;25(9):1047-52
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of teenagers and young adults with ependymoma: the Royal Marsden experience.
  • BACKGROUND: The outcome and clinical characteristics of teenagers and young adults (TYA) with ependymoma have not been well documented.
  • We report the Royal Marsden Hospital experience treating TYA with ependymoma.
  • MATERIALS AND METHODS: Sixteen TYA were treated for ependymoma from 1971 to 2004 and are compared to 24 children (not infants) treated in the same period.
  • Up to 56% of patients treated in the paediatric unit received psychosocial support vs. 42.9% of patients treated in the adult unit.
  • DISCUSSION: Ependymoma in adolescents and young adults is an infrequent entity, with perhaps better outcome compared to children.
  • Providing adolescents with ependymoma the appropriate neuro-oncologic care, including access to multidisciplinary teams, full access to clinical trials and age-appropriate neuro-oncologic ancillary support services, remains a challenge.
  • [MeSH-major] Brain Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / therapy. Social Support. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2009 Feb;45(3):328-34 [19135358.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2643-50 [14642926.001]
  • [Cites] Oncologist. 2007 Jul;12(7):816-24 [17673613.001]
  • [Cites] Oncologist. 2006 Jun;11(6):590-601 [16794238.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):255-61 [15332330.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):242-55 [17626120.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2600-10 [14642922.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1812-6 [4027918.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):830-5 [18728673.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v119-27 [14684502.001]
  • [Cites] J Adolesc Health. 1997 Dec;21(6):366-73 [9401854.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v9-13 [14684497.001]
  • [Cites] Cancer. 2006 Oct 1;107(7 Suppl):1645-55 [16906507.001]
  • (PMID = 19533154.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Hamilton DW, Lusher ME, Lindsey JC, Ellison DW, Clifford SC: Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett; 2005 Sep 8;227(1):75-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma.
  • To investigate the role of aberrant epigenetic events in ependymoma and identify critical genes in its pathogenesis, the methylation status of nine tumour suppressor genes (TSGs: p14(ARF), p15(INK4B), p16(INK4A), CASP8, MGMT, TIMP3, TP73, RB1 and RASSF1A) was assessed.
  • Extensive hypermethylation across the RASSF1A CpG island was detected frequently in ependymomas of all clinical and pathological disease subtypes (86% of cases, n=35), but not in non-neoplastic brain tissues (n=6).
  • RASSF1A hypermethylation represents the most common gene-specific defect identified in ependymoma highlighting the importance of its further investigation in this disease.
  • [MeSH-major] Ependymoma / genetics. Genes, Tumor Suppressor. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. CpG Islands. DNA Methylation. Epigenesis, Genetic. Female. Humans. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051033.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schöttler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S: Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol; 2010 Jul 1;28(19):3182-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular staging of intracranial ependymoma in children and adults.
  • PURPOSE: The biologic behavior of intracranial ependymoma is unpredictable on the basis of current staging approaches.
  • We aimed at the identification of recurrent genetic aberrations in ependymoma and evaluated their prognostic significance to develop a molecular staging system that could complement current classification criteria.
  • PATIENTS AND METHODS: As a screening cohort, we studied a cohort of 122 patients with ependymoma before standardized therapy by using array-based comparative genomic hybridization.
  • DNA copy-number aberrations identified as possible prognostic markers were validated in an independent cohort of 170 patients with ependymoma by fluorescence in situ hybridization analysis.
  • [MeSH-major] Brain Neoplasms / genetics. Comparative Genomic Hybridization / methods. Ependymoma / genetics. In Situ Hybridization, Fluorescence / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosome Aberrations. Cohort Studies. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Gene Deletion. Gene Dosage. Humans. Male. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Neurol. 2010 Aug;6(8):414 [20718114.001]
  • (PMID = 20516456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


17. Spengos K, Vassilopoulou S, Tsivgoulis G, Karachalios G, Vassilopoulos D: Superficial siderosis due to a lumbar ependymoma mimicking adult-onset spinocerebellar ataxia. Clin Neurol Neurosurg; 2007 Oct;109(8):705-7
Genetic Alliance. consumer health - Spinocerebellar Ataxia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial siderosis due to a lumbar ependymoma mimicking adult-onset spinocerebellar ataxia.
  • Superficial siderosis (SS), as a result of chronic subarachnoid haemorrhage and haemosiderin deposition on the leptomeninges and subpial layers of the brain, cerebellum and spinal cord, can cause ataxia, pyramidal tract lesions and hearing deficits.
  • In cases with not pronounced hearing impairment adult-onset spinocerebellar ataxia can be considered as a differential diagnostic alternative.
  • A bleeding lumbar ependymoma was identified as a source of haemorrhage.
  • [MeSH-major] Ependymoma / complications. Siderosis / diagnosis. Siderosis / etiology. Spinal Cord Neoplasms / complications. Spinocerebellar Ataxias / diagnosis

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Siderosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555872.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Cui Y, Zhao JZ: [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them]. Zhonghua Yi Xue Za Zhi; 2008 Dec 23;88(47):3356-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them].
  • OBJECTIVE: To study the expression of epidermal growth factor receptor (EGFR) and Ki-67 antigen in human brain ependymoma and the correlation between them.
  • METHODS: Immunohistochemistry was used to detect the expression of EGFR and Ki-67 antigen in 40 specimens of brain ependymoma, 8 specimens of normal brain tissues, and 8 specimens of glioblastoma, all obtained during operation.
  • RESULTS: The EGFR positive rate of the III - IV grade ependymoma tissues was 75%, significantly higher than that of the grade I - II grade ependymoma tissues (25%, P < 0.05).
  • The EGFR positive rate of the recurrent ependymoma tissues (5/6) was significantly higher than that of the primary ependymoma tissues (9/34, P < 0.05).
  • The positive rate of Ki-67 L1 in the III - IV grade ependymoma tissues was (9.5 +/- 5.6)%, significantly higher than that in the grade I - II grade ependymoma tissues [(2.2 +/- 1.4)%, P < 0.05)].
  • The positivity of EGFR was positively correlated with the grade level of ependymoma and Ki-67 L1 positivity (both P < 0.01).
  • The positive rate of recurrent ependymoma is higher than that of the primary ependymoma.
  • [MeSH-major] Brain Neoplasms / metabolism. Ependymoma / metabolism. Ki-67 Antigen / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257969.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


19. Ertan Y, Sarsik B, Ozgiray E, Kitis O, Dalbasti T, Akalin T: Pigmented ependymoma with signet-ring cells and Rosenthal fibers: a rare variant of ependymoma. Neuropathology; 2010 Feb 1;30(1):71-5
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented ependymoma with signet-ring cells and Rosenthal fibers: a rare variant of ependymoma.
  • We report a rare case of ependymoma with vacuolar features, signet cells, pigmentation and numerous Rosenthal fibers arising in the fourth ventricle of a 35-year-old woman.
  • The case is presented to increase familiarity with these extraordinary variants of ependymoma.
  • [MeSH-major] Brain / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Fourth Ventricle / pathology. Pigmentation
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508348.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Terasaki M, Uchikado H, Takeuchi Y, Shigemori M: Minimally invasive management of ependymoma of the aqueduct of Sylvius: therapeutic considerations and management. Minim Invasive Neurosurg; 2005 Dec;48(6):322-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive management of ependymoma of the aqueduct of Sylvius: therapeutic considerations and management.
  • The case of an adult male with focal aqueductal ependymoma who presented with the clinical syndrome of hydrocephalus is reported.
  • This may be of particular interest because it represents the first case of aqueductal ependymoma that has been successfully treated with endoscopic surgery.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebral Aqueduct / pathology. Cerebral Aqueduct / surgery. Ependymoma / surgery. Neuroendoscopy / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432779.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Arsene D, Gherghiceanu M, Ardeleanu C, Danaila L: Highly cystic brain tumor: rare histological features in an ependymoma. Neuropathology; 2007 Aug;27(4):378-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly cystic brain tumor: rare histological features in an ependymoma.
  • Ependymoma is a slowly growing tumor appearing mostly in children and young adults.
  • [MeSH-major] Brain Neoplasms / ultrastructure. Cysts / ultrastructure. Ependymoma / ultrastructure
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fourth Ventricle / ultrastructure. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899693.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


22. Kurimoto M, Nagai S, Hamada H, Tsuboi Y, Hayashi N, Kubota T, Endo S: Malignant transformation of supratentorial clear cell ependymoma. Neuropathology; 2009 Jun;29(3):299-302
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of supratentorial clear cell ependymoma.
  • Recurrence of clear cell ependymoma is not a rare condition, but malignant transformation of clear cell ependymoma has not yet been well presented.
  • A brain tumor in the left frontal premotor area was removed and an initial pathological diagnosis of oligodendroglioma was made.
  • At this time, the tumor had an ultrastructural appearance compatible with ependymoma.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Brain / pathology. Brain / ultrastructure. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647267.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


23. Ferroli P, Russo A, Albanese E, Tringali G, Broggi G: Gravity-aided trans-falcine removal of a contralateral subcortical ependymoma. Acta Neurochir (Wien); 2007 Nov;149(11):1147-50; discussion 1150
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gravity-aided trans-falcine removal of a contralateral subcortical ependymoma.
  • We report a 32-year-old woman with an ependymoma of the medial surface of the left Rolandic area that was completely removed through a contralateral gravity-aided, image-guided transfalcine approach.
  • [MeSH-major] Brain Neoplasms / surgery. Craniotomy / methods. Ependymoma / surgery. Microsurgery / methods. Neuronavigation / methods. Temporal Lobe / surgery
  • [MeSH-minor] Adult. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Gravitation. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712517.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


24. Vitanovics D, Bálint K, Hanzély Z, Banczerowski P, Afra D: Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res; 2010 Mar;16(1):93-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma in adults: surgery, reoperation and radiotherapy for survival.
  • PURPOSE: to retrospectively determine the long-term outcome of adult intracranial ependymoma patients treated with surgery, reoperation, and postoperative radiation therapy.
  • Forty patients had World Health Organization (WHO) Grade II ependymoma, and 21 patients had Grade III ependymoma.
  • CONCLUSION: In our experience the use of radiotherapy in adult, intracranial WHO Grade II ependymoma patients had no significant effect on prognosis.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Ependymoma / mortality. Ependymoma / therapy. Neurosurgical Procedures
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Radiotherapy. Reoperation. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728165.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Liu AK, Foreman NK, Gaspar LE, Trinidad E, Handler MH: Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer; 2009 Jul;52(7):804-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children.
  • BACKGROUND: Treatment failure in children with ependymoma is relatively common, with the majority of events consisting of local failure.
  • To minimize the duration of therapy, we chose a hypofractionated regimen that has been shown to be well tolerated in adult patients.
  • PROCEDURE: We performed a review of the experience at the Children's Hospital in Denver and at the Department of Radiation Oncology at the University of Colorado Denver from 1995 to 2008 with hypofractionated re-irradiation after maximally safe resection in children with locally recurrent ependymoma.
  • RESULTS: Six children with locally recurrent ependymoma were seen in that time period.
  • CONCLUSIONS: Hypofractionated re-irradiation after resection for locally recurrent ependymoma is well tolerated.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Ependymoma / radiotherapy. Ependymoma / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery


26. Yan X, Cheng X, Liu J, Luo D, He X, Chen F, Qin C, Wang Y: Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma. Clin Invest Med; 2008;31(4):E206-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.
  • Tissue samples obtained from 15 patients with brain contusion were used as control.
  • Positive cell rates were 2.65+/-0.83 % in the low-grade, 9.63+/-0.08 % in the mid-grade, and 28.41+/-0.71 % in the high-grade ependymoma groups.
  • In the mid-grade ependymoma group eNOS was expressed moderately in 10 cases and intensely in 15.
  • CONCLUSION: Ki-67 and eNOS expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.
  • [MeSH-major] Brain Neoplasms. Ependymoma. Gene Expression Regulation / drug effects. Ki-67 Antigen / therapeutic use. Nitric Oxide Synthase Type III / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682044.001).
  • [ISSN] 1488-2353
  • [Journal-full-title] Clinical and investigative medicine. Médecine clinique et experimentale
  • [ISO-abbreviation] Clin Invest Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


27. Mizuno J, Nakagawa H, Inoue T, Kondo S, Hara K, Hashizume Y: Signet-ring cell ependymoma with intratumoral hemorrhage in the medulla oblongata. J Clin Neurosci; 2005 Aug;12(6):711-4
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell ependymoma with intratumoral hemorrhage in the medulla oblongata.
  • We report a case of signet-ring cell ependymoma of the medulla oblongata.
  • However, the final paraffin section showed an ependymoma with signet-ring cells.
  • Signet-ring cell ependymoma must be included in the differential diagnosis of metastatic carcinoma to the central nervous system.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Carcinoma, Signet Ring Cell / pathology. Ependymoma / pathology. Intracranial Hemorrhages / pathology. Medulla Oblongata
  • [MeSH-minor] Adult. Child. Child, Preschool. Female. Humans. Immunohistochemistry / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Mucin-1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115557.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


28. Preusser M, Heinzl H, Gelpi E, Höftberger R, Fischer I, Pipp I, Milenkovic I, Wöhrer A, Popovici F, Wolfsberger S, Hainfellner JA: Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology; 2008 Jul;53(1):39-47
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker.
  • AIMS: The Ki67 tumour cell proliferation index is an independent prognostic factor in ependymoma patients.
  • To this end, the aim was to analyse systematically inter- and intraobserver agreement and reproducibility of the prognostic impact of the Ki67 index in intracranial ependymoma.
  • METHODS AND RESULTS: The study cohort contained 78 cases of intracranial ependymoma.
  • CONCLUSIONS: Our data show that the Ki67 index in intracranial ependymoma is a reproducible and robust prognostic factor and can be considered a promising histopathological candidate biomarker.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Ependymoma / pathology. Ki-67 Antigen / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Cell Proliferation. Child. Child, Preschool. Humans. Immunohistochemistry. Infant. Middle Aged. Observer Variation. Prognosis. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613924.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


29. Shintaku M, Nagata N, Itoh H: Tanycytic ependymoma of the spinal cord with anaplastic cytological features. Brain Tumor Pathol; 2009;26(1):7-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanycytic ependymoma of the spinal cord with anaplastic cytological features.
  • This is the first documentation of tanycytic ependymoma in which tumor cells showed anaplastic cytological features.
  • [MeSH-major] Ependymoma / pathology. Spinal Cord / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Anaplasia / pathology. Humans. Immunohistochemistry. Ki-67 Antigen / immunology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Anaplastic Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408091.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


30. Schroeder TM, Chintagumpala M, Okcu MF, Chiu JK, Teh BS, Woo SY, Paulino AC: Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys; 2008 Jul 15;71(4):987-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy in childhood ependymoma.
  • PURPOSE: To determine the patterns of failure after intensity-modulated radiation therapy (IMRT) for localized intracranial ependymoma.
  • METHODS AND MATERIALS: From 1994 to 2005, 22 children with pathologically proven, localized, intracranial ependymoma were treated with adjuvant IMRT.
  • At last follow-up, no patient had developed visual loss, brain necrosis, myelitis, or a second malignancy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Humans. Infant. Male. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258381.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, Genitori L, Giordano F, Riccardi R, Schoenmakers EF, Massimino M, Sozzi G: Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol; 2006 Nov 20;24(33):5223-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.
  • PURPOSE: To delineate clinically relevant molecular signatures of intracranial ependymoma.
  • An ependymoma-specific gene expression signature was characterized by the concurrent abnormal expression of developmental and differentiation pathways, including NOTCH and sonic hedgehog signaling.
  • Integrated genomic and expression profiling allowed us to identify genes of which the expression is deregulated in intracranial ependymoma, such as overexpression of the putative proto-oncogene YAP1 (located at 11q22) and downregulation of the SULT4A1 gene (at 22q13.3).
  • [MeSH-major] Brain Neoplasms / genetics. Ependymoma / genetics. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adolescent. Adult. Child. Child, Preschool. DNA Methylation. Down-Regulation. Female. Gene Expression Profiling. Humans. In Situ Hybridization, Fluorescence. Infant. Loss of Heterozygosity. Male. Oligonucleotide Array Sequence Analysis. Phosphoproteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sulfotransferases / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114655.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Phosphoproteins; 0 / YAP1 (Yes-associated) protein, human; EC 2.8.2 / SULT4A1 protein, human; EC 2.8.2.- / Sulfotransferases
  •  go-up   go-down


32. Shu HK, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN, Fisher MJ: Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer; 2007 Jul 15;110(2):432-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood intracranial ependymoma: twenty-year experience from a single institution.
  • BACKGROUND: Because few large studies of pediatric ependymoma treatment are available, the authors believed that a retrospective review of treatment outcomes from a single institution would yield potentially valuable information regarding potential prognostic factors.
  • METHODS: Medical records were reviews of patients with intracranial ependymoma who received their initial treatment at the Children's Hospital of Philadelphia (CHOP)/Hospital of the University of Pennsylvania (HUP) between January 1980 and December 2000.
  • CONCLUSIONS: In this study of patients with pediatric intracranial ependymoma, OS and PFS rates were concordant with the rates published in other modern series.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Prognosis. Survival Analysis. Treatment Outcome


33. Merchant TE, Kiehna EN, Li C, Xiong X, Mulhern RK: Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. Int J Radiat Oncol Biol Phys; 2005 Dec 01;63(5):1546-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma.
  • PURPOSE: To assess the effects of radiation dose-volume distribution on the trajectory of IQ development after conformal radiation therapy (CRT) in pediatric patients with ependymoma.
  • METHODS AND MATERIALS: The study included 88 patients (median age, 2.8 years +/- 4.5 years) with localized ependymoma who received CRT (54-59.4 Gy) that used a 1-cm margin on the postoperative tumor bed.
  • Differential dose-volume histograms (DVH) were derived for total-brain, supratentorial-brain, and right and left temporal-lobe volumes.
  • For all patients, IQ was best estimated by age (years) at CRT; percent volume of the supratentorial brain that received doses between 0 and 20 Gy, 20 and 40 Gy, and 40 and 65 Gy; and time (months) after CRT.
  • CONCLUSION: Radiation dosimetry can be used to predict IQ after CRT in patients with localized ependymoma.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy. Intelligence / radiation effects. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Algorithms. Child. Child, Preschool. Female. Humans. Infant. Intelligence Tests. Male. Prospective Studies. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115736.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Hwang HJ, Sohn JH, Han SJ, Kim TS, Lee YS, Kim JH: Multi-disciplinary treatment of a rare pelvic cavity ependymoma. Yonsei Med J; 2007 Aug 31;48(4):719-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-disciplinary treatment of a rare pelvic cavity ependymoma.
  • Here, we present an ependymoma arising from the pelvic cavity.
  • The tumor was thus diagnosed as an ependymoma arising from the pelvic cavity.
  • This is a rare case of extraneural ependymoma for which an in vitro chemosensitivity test was critical in determining the multidisciplinary approach for treatment.
  • [MeSH-major] Ependymoma / pathology. Pelvic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2001 Feb;33(1):26-9 [11280604.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):421-3 [12946033.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):203-9 [6703196.001]
  • [Cites] Mayo Clin Proc. 1992 Apr;67(4):373-8 [1548954.001]
  • [Cites] Arch Pathol Lab Med. 1985 Mar;109(3):291-3 [3838461.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):62-8 [3522133.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2565-71 [2684388.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):20-7 [1985717.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):632-8 [6204919.001]
  • (PMID = 17722249.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628065
  •  go-up   go-down


35. Kano T, Ikota H, Wada H, Iwasa S, Kurosaki S: A case of an anaplastic ependymoma with gliosarcomatous components. Brain Tumor Pathol; 2009;26(1):11-7
Genetic Alliance. consumer health - Anaplastic Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of an anaplastic ependymoma with gliosarcomatous components.
  • Pathological studies revealed a mixed glioblastoma multiforme and anaplastic ependymoma.
  • Subtotal removal of the tumor was performed; pathological studies revealed an anaplastic ependymoma with sarcomatous components.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Ependymoma / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Female. Glial Fibrillary Acidic Protein / metabolism. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Paraffin Embedding. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408092.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


36. Schuurmans M, Vanneste JA, Verstegen MJ, van Furth WR: Spinal extramedullary anaplastic ependymoma with spinal and intracranial metastases. J Neurooncol; 2006 Aug;79(1):57-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal extramedullary anaplastic ependymoma with spinal and intracranial metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cervical Vertebrae. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Lumbar Vertebrae. Magnetic Resonance Imaging. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Anaplastic Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614942.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


37. Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slavc I, Harris AL, Acker T, Budka H, Hainfellner JA: Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol; 2005 Feb;109(2):211-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival.
  • We investigated angiogenic patterns and expression of hypoxia-related tissue factors and their prognostic impact in 100 cases of intracranial ependymoma.
  • We conclude that bizarre vascular pattern, necrosis and high hypoxia score are frequently detectable in intracranial ependymoma, but seem less important for patient outcome than tumor cell proliferation.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / metabolism. Carbonic Anhydrases / metabolism. Ependymoma / metabolism. Neovascularization, Pathologic. Transcription Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Hypoxia-Inducible Factor 1, alpha Subunit. Immunohistochemistry / methods. In Situ Hybridization / methods. Infant. Male. Middle Aged. Regression Analysis. Retrospective Studies. Survival Analysis. Time Factors. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614581.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


38. Arai T, Tani S, Isoshima A, Nagashima H, Joki T, Takahashi-Fujigasaki J, Abe T: [Intraoperative photodynamic diagnosis for spinal ependymoma using 5-aminolevulinic acid: technical note]. No Shinkei Geka; 2006 Aug;34(8):811-7
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative photodynamic diagnosis for spinal ependymoma using 5-aminolevulinic acid: technical note].
  • OBJECTIVE: The fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) is a well established method for the treatment of brain tumor, especially malignant glioma.
  • In the present study, we evaluated the usefulness of PDD for spinal ependymoma using 5-ALA.
  • METHODS: Three patients with spinal ependymoma received oral doses of 5-ALA (20 mg/kg body weight) 2 hours before anesthesia induction.
  • CONCLUSION: The results of this study indicate the usefulness of 5-ALA-induced tumor fluorescence in guiding resection of spinal ependymoma.
  • [MeSH-major] Aminolevulinic Acid. Ependymoma / diagnosis. Photosensitizing Agents. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Fluorescence. Humans. Intraoperative Period. Lighting. Magnetic Resonance Imaging. Male. Middle Aged. Porphyrins. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910494.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


39. Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC: Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol; 2005 Oct;64(10):875-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma.
  • We present 8 examples of a neoplasm with features of both astrocytoma and ependymoma that may represent a distinct clinicopathologic entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Ependymoma / pathology. Epilepsy / etiology. Glioma / complications. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy, Electron. Mucin-1 / metabolism


40. Wright KD, Gajjar A: New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst; 2009 Oct;25(10):1275-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
  • INTRODUCTION: With the limited role of current treatment regimens and potential associated side effects of radiation in young children with ependymoma, considerable effort is being focused on new chemotherapeutic strategies and biologic agents.
  • DISCUSSION AND CONCLUSION: Identification of those molecular changes underlying the development of ependymoma may, in time, lead to the development of not only novel therapeutic agents, but also specific patient-tailored therapies directed against known cell-signaling pathways.

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Mar-Apr;20(2):125-30 [9544162.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3932-41 [9731505.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Sep;27(9):486-90 [16189442.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):452-64 [16212810.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):432-41 [17559078.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):231-5 [17610266.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):418-24 [18245671.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):209-16 [18386816.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Oct;8(10):1545-57 [18925847.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):701-7 [19147777.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4143-55 [10590059.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1248-57 [10882863.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81 [16282886.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):1-3 [16330665.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Annu Rev Med. 2006;57:83-97 [16409138.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1522-8 [16575002.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] J Chemother. 2006 Apr;18(2):188-91 [16736888.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2335-42 [16899365.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):876-85 [17036041.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Nov;28(11):720-8 [17114958.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1511-5 [17332296.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):705-12 [11531256.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):45S-51S [11560971.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):73-80 [11863115.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):140-8 [12517790.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):12-20 [12644980.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1643-8 [14534880.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Nov;52(5):377-82 [12879280.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):941-9 [14967454.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1212-8 [14977817.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Cancer Treat Rep. 1982 Dec;66(12):2013-20 [6890409.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):62-6 [2826716.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):408-17 [2303876.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(2):57-65 [2132926.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):249-56 [1732426.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):283-90 [1517804.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):119-25 [8870014.001]
  • [Cites] J Neurooncol. 1997 May;32(3):243-52 [9049886.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):856-60; discussion 860 [9092863.001]
  • [Cites] Med Pediatr Oncol. 1997 Jul;29(1):28-32 [9142202.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(4):609-15 [9274443.001]
  • (PMID = 19212772.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS85887; NLM/ PMC2738756
  •  go-up   go-down


41. Qian X, Goumnerova LC, De Girolami U, Cibas ES: Cerebrospinal fluid cytology in patients with ependymoma: a bi-institutional retrospective study. Cancer; 2008 Oct 25;114(5):307-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid cytology in patients with ependymoma: a bi-institutional retrospective study.
  • BACKGROUND: Ependymoma cells are known to occasionally exfoliate into cerebrospinal fluid (CSF).
  • However, the frequency of CSF involvement in patients with ependymoma is unclear, and to the authors' knowledge the cytomorphologic features of the tumor cells have not been described in detail to date.
  • In this study, the CSF findings in patients with ependymal neoplasms are summarized and the cytomorphologic features of ependymoma, including its variants, are illustrated.
  • METHODS: A search of the pathology databases of 2 medical centers was performed to identify all patients with a histologic diagnosis of ependymoma in whom CSF samples were examined.
  • RESULTS: In all, 177 patients with a diagnosis of ependymoma were identified.
  • Of the 8 patients with positive and/or suspicious diagnoses, 5 ependymomas exhibited anaplastic features and 1 tumor was a myxopapillary ependymoma.
  • The positive samples were usually hypercellular, with cohesive epithelioid cells; long cytoplasmic processes resembling bipolar tanycytes were observed in the tanycytic variant of ependymoma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Brain Neoplasms / pathology. Ependymoma / cerebrospinal fluid. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies


42. Zhang S, Wang X, Zhang Z, Chen Y: Tanycytic ependymoma arising from the right lateral ventricle: a case report and review of the literature. Neuropathology; 2008 Aug;28(4):427-32
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanycytic ependymoma arising from the right lateral ventricle: a case report and review of the literature.
  • Four cases of tanycytic ependymoma arising from the lateral ventricle have been reported in literature.
  • Tanycytic ependymoma has slightly better prognosis than other ependymoma subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312548.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


43. Jain A, Rishi A, Suri V, Garg A, Sharma MC, Sarkar C, Sharma BS: Recurrent ependymoma with cartilaginous metaplasia in an adult: report of a rare case and review of literature. Clin Neuropathol; 2009 Mar-Apr;28(2):101-4
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ependymoma with cartilaginous metaplasia in an adult: report of a rare case and review of literature.
  • The present report discusses an unusual case of ependymoma with cartilaginous metaplasia in a 21-year-old male.
  • [MeSH-major] Cartilage / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Brain / pathology. Humans. Magnetic Resonance Imaging. Male. Metaplasia. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19353841.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


44. McGuire CS, Sainani KL, Fisher PG: Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg; 2009 Apr;110(4):725-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study.
  • OBJECT: Previous small studies disagree about which clinical risk factors influence ependymoma incidence.
  • CONCLUSIONS: Males have a higher incidence of ependymoma than do females.
  • Ependymoma occurs within the CNS at distinct locations at different ages, consistent with hypotheses postulating distinct populations of radial glial stem cells within the CNS.
  • Ependymoma incidence appears to have increased over the past 3 decades, but only in adults.
  • [MeSH-major] Brain Neoplasms / epidemiology. Ependymoma / epidemiology. Spinal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. SEER Program. Sex Factors. United States / epidemiology


45. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, Luchtman-Jones L, Rich KM, Grigsby PW, Lockett MA, Wahab SH, Simpson JR: Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):387-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiation therapy for grade II and III intracranial ependymoma.
  • PURPOSE: To retrospectively determine the long-term outcome of intracranial ependymoma patients treated with surgery and postoperative radiation therapy.
  • Forty patients had World Health Organization Grade II ependymoma, and 20 patients had Grade III ependymoma.
  • CONCLUSION: Our long-term follow-up indicates that half of ependymoma patients will have disease recurrences, indicating the need for more effective treatments.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Female. Humans. Infant. Infratentorial Neoplasms / mortality. Infratentorial Neoplasms / radiotherapy. Infratentorial Neoplasms / surgery. Male. Middle Aged. Multivariate Analysis. Radiotherapy Dosage. Retrospective Studies. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / radiotherapy. Supratentorial Neoplasms / surgery. Survival Rate

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667957.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Barbagallo GM, Caltabiano R, Parisi G, Albanese V, Lanzafame S: Giant cell ependymoma of the cervical spinal cord: case report and review of the literature. Eur Spine J; 2009 Jul;18 Suppl 2:186-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell ependymoma of the cervical spinal cord: case report and review of the literature.
  • They develop from the ependymal cells that line the ventricular cavities of the brain and the central canal of the spinal cord, as well as from ependymal clusters in the filum terminale.
  • Giant cell ependymoma (GCE) is a rare subtype, with few cases reported, mostly in the brain.
  • We describe the case of a cervical spinal cord ependymoma with pleomorphic giant cells and focal calcifications occurring in a 25-year-old woman.
  • This case, the second giant-cell ependymoma to be described in the spinal cord and the first with focal calcifications, highlights the features of GCE and the discrepancy between the worrisome histological appearance, the surgical findings and the clinical relatively good prognosis.
  • [MeSH-major] Cervical Vertebrae. Ependymoma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 2001 Jan-Feb;20(1):31-7 [11220693.001]
  • [Cites] Pathol Int. 2003 Aug;53(8):539-46 [12895233.001]
  • [Cites] J Neurosurg. 2004 Jan;100(1 Suppl Spine):75-9 [14748579.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):880-3 [3286833.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):408-17 [2303876.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):729-36 [2378394.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):43-6 [8191646.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1091-101 [8764746.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):338-46 [9500776.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):398-403 [9578093.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):434-40 [9888153.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):367-8, 373 [16389948.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6):908-11 [17405264.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Feb;110(2):176-81 [18006220.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):77-85 [11763426.001]
  • (PMID = 18820954.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC2899556
  •  go-up   go-down


47. Lo SS, Abdulrahman R, Desrosiers PM, Fakiris AJ, Witt TC, Worth RM, Dittmer PH, Desrosiers CM, Frost S, Timmerman RD: The role of Gamma Knife Radiosurgery in the management of unresectable gross disease or gross residual disease after surgery in ependymoma. J Neurooncol; 2006 Aug;79(1):51-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Gamma Knife Radiosurgery in the management of unresectable gross disease or gross residual disease after surgery in ependymoma.
  • PURPOSE/OBJECTIVE: To evaluate the efficacy and the toxicity of Gamma Knife (GK)-based stereotactic radiosurgery (SRS) in the management of gross disease in ependymoma.
  • CONCLUSIONS: GK-based SRS appears to be a feasible and safe treatment modality for patients with ependymoma with unresectable gross disease or gross residual disease after surgery.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Survival Analysis. Survival Rate. Treatment Outcome


48. Saito R, Kumabe T, Kanamori M, Sonoda Y, Tominaga T: Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence. Neurosurg Rev; 2010 Apr;33(2):185-91; discussion 191-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence.
  • High resection rate, meticulous follow-up, and intensive treatment for recurrence improved the survival of patients with anaplastic ependymoma.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Ependymoma / mortality. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate


49. Wu WX, Yu SZ, Sun CY, Wang Q, Jin SM, An TL: [Detection of chromosomal imbalance in ependymoma by comparative genomic hybridization]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):148-52
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of chromosomal imbalance in ependymoma by comparative genomic hybridization].
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Ependymoma / genetics. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Comparative Genomic Hybridization. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575847.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


50. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA: Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol; 2009 Mar;10(3):258-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study.
  • BACKGROUND: Therapy for ependymoma includes aggressive surgical intervention and radiotherapy administered by use of methods that keep the risk of side-effects to a minimum.
  • METHODS: Between July 11, 1997, and Nov 18, 2007, 153 paediatric patients (median age 2.9 years [range 0.9-22.9 months]) with localised ependymoma were treated.
  • 85 patients had anaplastic ependymoma; the tumours of 122 were located in the infratentorial region, and 35 had received previous chemotherapy.
  • The incidence of secondary malignant brain tumour at 7 years was 2.3% (0-5.6) and brainstem necrosis 1.6% (0-4.0).
  • INTERPRETATION: Treatment of ependymoma should include surgery with the aim of gross-total resection and conformal, high-dose, postoperative irradiation.
  • [MeSH-major] Brain Neoplasms / therapy. Ependymoma / therapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Prospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2000;39(1):97-100 [10752661.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] J Neurosurg. 2002 Oct;97(4):827-35 [12405370.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1336-45 [15050308.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):255-61 [15332330.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):387-91 [15667957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1546-54 [16115736.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5283-90 [17114662.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):432-41 [17559078.001]
  • [Cites] Lancet Oncol. 2007 Aug;8(8):696-705 [17644039.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97 [18406885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):987-93 [18258381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):979-86 [18325681.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3965-70 [18711186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):892-9 [18395355.001]
  • [CommentIn] Lancet Oncol. 2009 Mar;10(3):206-7 [19261252.001]
  • (PMID = 19274783.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS429992; NLM/ PMC3615425
  •  go-up   go-down


51. Benesch M, Spiegl K, Winter A, Passini A, Lackner H, Moser A, Sovinz P, Schwinger W, Urban C: A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning. Childs Nerv Syst; 2009 Feb;25(2):173-81
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning.
  • BACKGROUND: The aim of this study was to quantify the severity of late effects by a simple numerical score (late effects severity score, LESS) in patients who received radiochemotherapy for medulloblastoma or ependymoma.
  • Twenty-three patients with medulloblastoma (n = 18) or ependymoma (n = 5) underwent extensive neurocognitive and QoL testing at a median of 56 months (range, 1-174) after the end of treatment.
  • RESULTS: Patients with medulloblastoma/ependymoma had significantly higher LESS and significantly lower Wechsler Adult Intelligence Scale (WAIS)/Wechsler Intelligence Scales for Children (WISC) scores compared to patients with LGG.
  • Comparison of QoL and late effects in patients with medulloblastoma/ependymoma demonstrated a significant negative correlation only for neurological late effects and the KINDL score suggesting that younger patients with more severe late effects reported on a worse QoL.
  • CONCLUSIONS: This LESS seems to be a simple and practical tool to quantify late effects in former brain tumor patients.
  • [MeSH-major] Ependymoma / therapy. Medulloblastoma / therapy. Nervous System Diseases / physiopathology. Quality of Life
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cognition / drug effects. Cognition / physiology. Cognition / radiation effects. Combined Modality Therapy / adverse effects. Drug-Related Side Effects and Adverse Reactions. Endocrine System / drug effects. Endocrine System / physiopathology. Endocrine System / radiation effects. Female. Follow-Up Studies. Hearing / drug effects. Hearing / physiology. Hearing / radiation effects. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Outcome Assessment (Health Care) / methods. Radiotherapy / adverse effects. Time Factors. Verbal Learning / drug effects. Verbal Learning / physiology. Verbal Learning / radiation effects. Vision, Ocular / drug effects. Vision, Ocular / physiology. Vision, Ocular / radiation effects. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Neuropediatrics. 2005 Dec;36(6):357-65 [16429375.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Qual Life Res. 1998 Jul;7(5):399-407 [9691720.001]
  • [Cites] Schweiz Arch Neurol Psychiatr (1985). 1990;141(1):21-30 [1690447.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3476-86 [10550145.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):135-8 [6722738.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2527-35 [16735705.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1580-6 [7066864.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3720-8 [10577843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):137-45 [10477017.001]
  • [Cites] J Pediatr. 1978 Dec;93(6):903-9 [214533.001]
  • [Cites] Childs Nerv Syst. 1990 Mar;6(2):60-5 [2340529.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Eur J Pediatr. 2000 Oct;159(10):750-8 [11039130.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] J Neurooncol. 2005 May;72(3):245-53 [15937648.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5493-500 [16110009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] Int J Cancer Suppl. 1999;12:83-6 [10679876.001]
  • [Cites] J Pediatr. 2002 Nov;141(5):683-8 [12410198.001]
  • [Cites] Pediatr Neurol. 2003 Jan;28(1):42-7 [12657419.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1004-10 [8189255.001]
  • [Cites] Arch Surg. 2007 Nov;142(11):1043-8 [18025331.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):199-205 [16739030.001]
  • (PMID = 18974990.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Yi W, Haapasalo H, Holmlund C, Järvelä S, Raheem O, Bergenheim AT, Hedman H, Henriksson R: Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age. Clin Neuropathol; 2009 Jan-Feb;28(1):21-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age.
  • The indications that expression and subcellular localization of LRIG proteins could be pathogenetically associated with specific clinicopathological features of ependymoma tumors might be of importance in the carcinogeneses and tumor progression of human ependymomas.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Membrane Proteins / biosynthesis. Spinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cell Nucleus / metabolism. Child. Child, Preschool. Cytoplasm / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Infant. Male. Membrane Glycoproteins / biosynthesis. Middle Aged. Tissue Array Analysis. World Health Organization


53. Pica A, Miller R, Villà S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert BG, Zaucha R, Haller G, Weber DC: The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1114-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network.
  • PURPOSE: The aim of this study was to assess the outcome of patients with primary spinal myxopapillary ependymoma (MPE).
  • Fifteen patients presented treatment failure at the primary site only, whereas 2 and 1 patients presented with brain and distant spinal failure only.
  • Three and 2 patients with local failure presented with concomitant spinal distant seeding and brain failure, respectively.
  • One patient failed simultaneously in the brain and spine.
  • CONCLUSIONS: The observed pattern of failure was mainly local, but one fifth of the patients presented with a concomitant spinal or brain component.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Brain Neoplasms / secondary. Child. Combined Modality Therapy / methods. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250760.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


54. Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR: Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol; 2008 May;88(1):65-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.
  • OBJECTIVES: We evaluated and compared tumor antigen precursor protein (TAPP) profiles in adult and pediatric brain tumors of 31 genes related to tumor associated antigens (TAA) for possible use in immunotherapy.
  • METHODS: Thirty-seven brain tumor specimens from 11 adult and 26 pediatric patients were analyzed by quantitative real-time PCR for the relative expression of 31 TAPP mRNAs.
  • RESULTS: The adult gliomas expressed 94% (29 of 31) of the TAPP mRNAs evaluated compared with pediatric brain tumors that expressed 55-74% of the TAPP mRNAs, dependent on tumor histological subtype.
  • (1) equal expression among adult and pediatric cases, (2) greater expression in adult than pediatric cases, (3) expression restricted to adult GBM and (4) a random distribution.
  • The pediatric brain tumors lacked expression of some genes associated with engendering tumor survival, such as hTert and Survivin.
  • CONCLUSIONS: The potential TAA targets identified from the TAPP profiles of 31 genes associated with adult and pediatric brain tumors may help investigators select specific target antigens for developing dendritic cell- or peptide-based vaccines or T cell-based immunotherapeutic approaches against brain tumors.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):337-44 [11676393.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] J Cell Biol. 1989 Dec;109(6 Pt 1):2575-87 [2687284.001]
  • [Cites] Hum Gene Ther. 1995 May;6(5):591-601 [7578396.001]
  • [Cites] Cancer Immunol Immunother. 1997 Oct;45(2):77-87 [9390198.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):882-3 [9525374.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):42-51 [9647171.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1359-65 [9880507.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Neuro Oncol. 2005 Jul;7(3):225-35 [16053697.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):342-63 [16389946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202 [16492905.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):4-13 [16534789.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1555-60 [16685456.001]
  • [Cites] Neurosurg Focus. 2000;9(6):e9 [16817692.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):905-13 [16957584.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1052-60 [16826191.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):139-48 [17004103.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-75 [17255279.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4960-3 [17785545.001]
  • [Cites] Immunology. 2007 Dec;122(4):615-22 [17645496.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):617-23 [10698506.001]
  • [Cites] J Neurooncol. 1999;45(2):141-57 [10778730.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2209-18 [10873070.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • (PMID = 18259692.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121258; United States / NINDS NIH HHS / NS / NS 046463; United States / NCI NIH HHS / CA / CA 121258; United States / NINDS NIH HHS / NS / R21 NS057829; United States / NINDS NIH HHS / NS / NS 054093; United States / NINDS NIH HHS / NS / NS 056300; United States / NINDS NIH HHS / NS / R21 NS056300; United States / NINDS NIH HHS / NS / R21 NS046463; United States / NINDS NIH HHS / NS / NS 057829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS572988; NLM/ PMC4005736
  •  go-up   go-down


55. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Four (80%) of these five patients suffered from disseminated disease of the central nervous system (CNS) at the time of presentation; this incidence is much higher than that reported in the combined adult and pediatric literature.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology


56. Jostel A, Mukherjee A, Hulse PA, Shalet SM: Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf); 2005 Jun;62(6):698-705
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors.
  • OBJECTIVE: Systematic collections of neuroimaging data are nonexistent in brain tumour survivors treated with adult growth hormone replacement therapy (AGHRT).
  • DESIGN: In 1993, our unit implemented a policy of performing brain scans on every brain tumour survivor before starting AGHRT, with repeat neuroimaging at least once after 12-18 months' treatment.
  • PATIENTS: All brain tumour survivors who received AGHRT (60 patients) were included in the analysis.
  • Of the 16 residual primary tumours, an incurable ependymoma continued to grow, and one meningioma progressed slightly in size over 7.7 years.
  • CONCLUSIONS: Our data do not suggest an increased rate of recurrence or progression of childhood brain tumours during AGHRT.
  • [MeSH-major] Brain Neoplasms. Growth Hormone / deficiency. Growth Hormone / therapeutic use. Hormone Replacement Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasm, Residual / diagnosis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943832.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


57. Rudà R, Gilbert M, Soffietti R: Ependymomas of the adult: molecular biology and treatment. Curr Opin Neurol; 2008 Dec;21(6):754-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymomas of the adult: molecular biology and treatment.
  • PURPOSE OF REVIEW: To review state of art and relevant advances in the molecular biology and management of ependymomas of the adult.
  • RECENT FINDINGS: Ependymomas of the adult are uncommon neoplasms of the central nervous system, and may occur either in the brain or the spinal cord.
  • Studies performed on genetic changes in ependymoma provide some insight into the pathogenesis and prognostic markers and yield new therapeutic targets, particularly focused on signal transduction modulators.
  • [MeSH-major] Ependymoma / genetics. Ependymoma / therapy. Molecular Biology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989122.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


58. Santi M, Quezado M, Ronchetti R, Rushing EJ: Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization. J Neurooncol; 2005 Mar;72(1):25-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.
  • The present study utilizes chromogenic in situ hybridization (CISH), a relatively recent hybridization technique, to retrospectively examine chromosome 7-copy number in pediatric and adult ependymomas.
  • Of the 27 hybridizations, polysomy of chromosome 7 was detected in 10 out of 15 (66%) adult ependymomas, and in only three out of 12 (25%) pediatric lesions.
  • The authors conclude that (1) there are distinct genetic subsets of ependymoma, in particular, increases in copy number of chromosome 7 are almost exclusively found in myxopapillary ependymoma, and that (2) CISH is a rapid and sensitive method of stratifying morphological variants of ependymoma and potentially other central nervous system (CNS) tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 7 / genetics. Ependymoma / genetics. Ploidies. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Chromogenic Compounds / analysis. Humans. In Situ Hybridization / methods. Infratentorial Neoplasms / classification. Infratentorial Neoplasms / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803371.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogenic Compounds
  •  go-up   go-down


59. Tseng JH, Merchant E, Tseng MY: Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales. Surg Neurol; 2006 Sep;66(3):258-63; discussion 263
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales.
  • BACKGROUND: To investigate the effects of SES and geographic variations on survival for adult patients with glioma, we analyzed data from 30489 patients from the Cancer Registry in England and Wales.
  • Age (HR, 1.04 per year from 15 years, P < .001), WHO grade (1.21 per grade from grade I, P < .001), and morphology (HR from 1.23 to 1.89, compared with ependymoma, P < .05) are the most influential factors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioma / epidemiology. Outcome Assessment (Health Care) / statistics & numerical data
  • [MeSH-minor] Adult. Age Distribution. Age Factors. Cost-Benefit Analysis. England / epidemiology. Ependymoma / diagnosis. Ependymoma / epidemiology. Ependymoma / physiopathology. Female. Geography. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / physiopathology. Prognosis. Registries / statistics & numerical data. Resource Allocation / trends. Sex Distribution. Socioeconomic Factors. State Medicine. Survival Rate. Wales / epidemiology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935629.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Guyotat J, Metellus P: [Intracranial ependymomas in adult patients. Prognostic factors, place of surgery and complementary treatment]. Neurochirurgie; 2007 Jun;53(2-3 Pt 1):85-94
MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial ependymomas in adult patients. Prognostic factors, place of surgery and complementary treatment].
  • Prognostic factors and optimal therapy for adult intracranial ependymoma are still debated.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Complementary Therapies / methods. Ependymoma / mortality. Ependymoma / pathology. Neurosurgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418281.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


61. Figarella-Branger D, Metellus P, Barrié M, Maues de Paula A, Fernandez C, Polivka M, Vital A, Labrousse F, Vignaud JM, Laquerrière A, Rousselet MC, Lacroix C, Saikali S, Chapon F, Gontier MF, Chrétien F, Babin P, Rigau V, Vandenbos F, Peoc'h M, Kujas M, Chinot O, Gouvernet J, Giorgi R, Guyotat J, Jouvet A: [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors]. Neurochirurgie; 2007 Jun;53(2-3 Pt 1):76-84
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors].
  • MATERIAL: Between 1990 and 2004, 216 adult patients with newly diagnosed ependymomas were treated in 19 French centers.
  • Eligibility required institutional histopathological confirmation of an ependymoma and available clinical history and MRI features (see comparison paper).
  • The potential prognostic value (overall survival OS and disease free survival DFS) of the following histological parameters was examined: perivascular pseudorosettes, ependymal rosettes, hyalinized vessels, mitotic index, microvascular proliferation, necrosis, area of increased cellularity, nuclear atypia, brain invasion and Mib-1 labelling index.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Ependymoma / mortality. Ependymoma / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Neoplasm Staging. Neurosurgical Procedures. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445840.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


62. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ: New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med; 2007 Feb;131(2):234-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors.
  • CONTEXT: Immunohistochemistry (IHC) has become an important tool in the diagnosis of brain tumors.
  • We discuss (1) placental alkaline phosphatase, c-Kit, and OCT4 for germinoma, (2) alpha-inhibin and D2-40 for capillary hemangioblastoma, (3) phosphohistone-H3 (PHH3), MIB-1/Ki-67, and claudin-1 for meningioma, (4) PHH3, MIB-1/Ki-67, and p53 for astrocytoma, (5) synaptophysin, microtubule-associated protein 2, neurofilament protein, and neuronal nuclei for medulloblastoma, (6) INI1 for atypical teratoid/rhabdoid tumor, and (7) epithelial membrane antigen for ependymoma.
  • All the markers presented here are used mainly for supporting or confirming the diagnosis, with the exception of the proliferation markers (MIB-1/Ki-67 and PHH3), which are primarily used to support grading and are reportedly associated with prognosis in certain categories of brain tumors.
  • In addition, IHC is also of great help in predicting the prognosis for certain brain tumors.
  • [MeSH-minor] Adult. Antibodies. Astrocytoma / diagnosis. Astrocytoma / metabolism. Child. Diagnosis, Differential. Ependymoma / diagnosis. Ependymoma / metabolism. Germinoma / diagnosis. Germinoma / metabolism. Hemangioblastoma / diagnosis. Hemangioblastoma / metabolism. Humans. Medulloblastoma / diagnosis. Medulloblastoma / metabolism. Meningioma / diagnosis. Meningioma / metabolism. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284108.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor
  • [Number-of-references] 96
  •  go-up   go-down


63. Bauer R, Dobesberger J, Unterhofer C, Unterberger I, Walser G, Bauer G, Trinka E, Ortler M: Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy. Acta Neurochir (Wien); 2007 Dec;149(12):1211-6; discussion 1216-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy.
  • Among these, 14 adult patients exhibited temporal lobe neoplasms associated with TLE.
  • Histological results: Astrocytoma 5 patients, ganglioglioma/gangliocytoma 5, oligodendroglioma 2, ependymoma 1 and dysembryoplastic neuroepithelial tumour (DNET) 1.
  • [MeSH-major] Brain Neoplasms / surgery. Epilepsy, Temporal Lobe / surgery. Postoperative Complications / etiology. Temporal Lobe / surgery
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / surgery. Electroencephalography. Ependymoma / surgery. Female. Follow-Up Studies. Ganglioglioma. Ganglioneuroma. Hemianopsia / etiology. Humans. Male. Middle Aged. Neuroectodermal Tumors, Primitive / surgery. Neurologic Examination. Oligodendroglioma / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940725.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


64. Tseng MY, Tseng JH: Survival analysis for adult glioma in England and Wales. J Formos Med Assoc; 2005 May;104(5):341-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis for adult glioma in England and Wales.
  • BACKGROUND AND PURPOSE: To investigate factors influencing survival for adult glioma at the national population level, data from the Cancer Registry in England and Wales were analyzed.
  • Patients with unspecified gliomas had the worst survival, while those with ependymoma had the best survival.
  • CONCLUSION: Survival in adult glioma is influenced by multiple factors, including socioeconomic background.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959601.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


65. Wang CC, Zhang JT, Liu AL: [Surgical management of brain-stem gliomas: a retrospective analysis of 311 cases]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb;27(1):7-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of brain-stem gliomas: a retrospective analysis of 311 cases].
  • OBJECTIVE: To further study the clinical features, diagnosis, and surgery outcome of brain-stem gliomas.
  • METHODS: Totally 311 patients with brain-stem gliomas received surgery operations in our hospital from 1980 to the end of 2001.
  • RESULTS: Different brain-stem gliomas showed different growth patterns.
  • Five years survival rate is 67% in ependymoma patients, 42% in astrocytoma patients.
  • None of brain-stem glioblastoma patients survived up to 5 years.
  • The patients with well-differentiated gliomas of brain-stem may be cured by microsurgical removal.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Ependymoma / surgery. Glioblastoma / surgery. Neurosurgical Procedures
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Mesencephalon / surgery. Microsurgery / methods. Middle Aged. Pons / surgery. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782484.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


66. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
  • Immunohistochemistry of 345 primary brain tumors demonstrated a strong cytoplasmic and weaker nuclear staining in 122 cases.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


67. Merchant TE, Pollack IF, Loeffler JS: Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol; 2010 Jan;20(1):58-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors across the age spectrum: biology, therapy, and late effects.
  • The clinical difference between brain tumors in adults and children is striking.
  • In this review of glioma, ependymoma, and medulloblastoma, we highlight the differences between adults and children, including the higher incidence of spinal cord ependymoma and supratentorial high-grade glioma in the adult and a higher incidence of medulloblastoma in the child.
  • An effort is underway to better characterize adult and pediatric brain tumors biologically with an emphasis on improving our understanding of tumor genesis, malignant transformation, and some of the similarities and differences between tumor types and their response to conventional therapy.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / therapy. Glioma / epidemiology. Glioma / therapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Combined Modality Therapy / methods. Disease Progression. Ependymoma / epidemiology. Ependymoma / therapy. Humans. Incidence. Infant. Infant, Newborn. Medulloblastoma / epidemiology. Medulloblastoma / therapy. Radiation Injuries. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 Mar;10(3):258-66 [19274783.001]
  • [Cites] Brain Pathol. 2009 Jan;19(1):81-90 [18452568.001]
  • [Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Neurooncol. 2009 Jul;93(3):343-8 [19142584.001]
  • [Cites] Histopathology. 2000 Nov;37(5):437-44 [11119125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):52-7 [12007941.001]
  • [Cites] J Pathol. 2002 Jun;197(2):238-44 [12015749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):855-60 [12377339.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):755-61 [14529781.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):629-36 [15871504.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8853-62 [16314645.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):313-9 [16200343.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Brain Pathol. 2007 Apr;17(2):146-50 [17388945.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Brain. 2007 May;130(Pt 5):1338-49 [17449478.001]
  • [Cites] Neurochirurgie. 2007 Jun;53(2-3 Pt 1):66-75 [17475290.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7 [17892918.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3691-7 [19581535.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3598-604 [19581536.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):391-8 [19330288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):496-503 [19464817.001]
  • [Cites] Childs Nerv Syst. 2009 Oct;25(10):1261-8 [19373477.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1568-74 [18278809.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jun;132(6):993-1007 [18517285.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3965-70 [18711186.001]
  • [Cites] Curr Opin Neurol. 2008 Dec;21(6):754-61 [18989122.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1627-36 [19255330.001]
  • (PMID = 19959032.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  • [Other-IDs] NLM/ NIHMS425593; NLM/ PMC3529408
  •  go-up   go-down


68. Kan P, Couldwell WT: Posterior fossa brain tumors and arterial hypertension. Neurosurg Rev; 2006 Oct;29(4):265-9; discussion 269
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior fossa brain tumors and arterial hypertension.
  • Much less information is available on the association between neurogenic hypertension and posterior fossa brain tumors.
  • To review the relationship between posterior fossa brain tumors and hypertension, we detail the history, basic science, and clinical reports along with an illustrative case regarding this topic.
  • [MeSH-major] Ependymoma / complications. Hypertension / etiology. Infratentorial Neoplasms / complications
  • [MeSH-minor] Adult. Antihypertensive Agents / therapeutic use. Blood Pressure / physiology. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1980 Jun;6(6):615-22 [7432603.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):834-41 [1614583.001]
  • [Cites] J Neurophysiol. 1946 May;9:205-17 [21028163.001]
  • [Cites] Surg Neurol. 2001 Jan;55(1):2-10; discussion 10-1 [11248294.001]
  • [Cites] Lancet. 1994 Nov 26;344(8935):1466-70 [7968120.001]
  • [Cites] J Hypertens. 1996 Nov;14(11):1317-24 [8934360.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):1-6; discussion 6-9 [9657182.001]
  • [Cites] Mt Sinai J Med. 1989 Jan;56(1):56-8 [2784184.001]
  • [Cites] Postgrad Med J. 1995 Jun;71(836):371-2 [7644403.001]
  • [Cites] Brain Res. 1982 Oct 14;249(2):223-35 [6128058.001]
  • [Cites] Ann Intern Med. 1985 Jan;102(1):42-9 [3966744.001]
  • [Cites] Clin Exp Hypertens. 1995 Jan-Feb;17(1-2):101-13 [7735261.001]
  • [Cites] J Neurosurg. 1992 Jul;77(1):103-12 [1307855.001]
  • [Cites] J Comp Neurol. 1996 Sep 9;373(1):62-75 [8876463.001]
  • [Cites] N Engl J Med. 1972 Jun 29;286(26):1397-9 [5030024.001]
  • [Cites] Stroke. 2001 Dec 1;32(12):2950-5 [11740004.001]
  • [Cites] J Neurosci. 1984 Feb;4(2):474-94 [6699683.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):35-41 [11752019.001]
  • [Cites] Hypertension. 2000 Jul;36(1):78-82 [10904016.001]
  • [Cites] Surg Forum. 1979;30:431-2 [538657.001]
  • [Cites] J Hypertens Suppl. 1999 Aug;17(3):S11-4 [10489093.001]
  • [Cites] Ann Surg. 1985 Aug;202(2):253-61 [4015232.001]
  • [Cites] Lancet. 1970 Mar 7;1(7645):492-4 [4190179.001]
  • [Cites] Scand Cardiovasc J Suppl. 1998;47:9-14 [9540128.001]
  • [Cites] Brain Res. 1994 Nov 7;663(1):107-20 [7531595.001]
  • [Cites] Prog Brain Res. 1989;81:49-79 [2694224.001]
  • [Cites] Hypertension. 1994 Dec;24(6):648-52 [7527793.001]
  • [Cites] Stroke. 1997 Sep;28(9):1749-54 [9303020.001]
  • [Cites] Hypertension. 1994 Oct;24(4):439-44 [8088908.001]
  • [Cites] J Comp Neurol. 1988 Jul 15;273(3):301-17 [2905364.001]
  • [Cites] Prog Brain Res. 1989;81:265-77 [2616786.001]
  • [Cites] J Hypertens. 1999 Sep;17(9):1257-63 [10489102.001]
  • [Cites] Hypertension. 2005 Oct;46(4):982-5 [16087783.001]
  • [Cites] Hypertension. 1996 Jan;27(1):36-42 [8591885.001]
  • [Cites] Lancet. 1998 Aug 8;352(9126):446-9 [9708753.001]
  • [Cites] J Comp Neurol. 1985 Sep 8;239(2):127-54 [2864362.001]
  • (PMID = 16924459.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  • [Number-of-references] 39
  •  go-up   go-down


69. Tamiolakis D, Papadopoulos N, Venizelos I, Lambropoulou M, Nikolaidou S, Bolioti S, Kiziridou A, Manavis J, Alexiadis G, Simopoulos C: Loss of chromosome 1 in myxopapillary ependymoma suggests a region out of chromosome 22 as critical for tumour biology: a FISH analysis of four cases on touch imprint smears. Cytopathology; 2006 Aug;17(4):199-204
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of chromosome 1 in myxopapillary ependymoma suggests a region out of chromosome 22 as critical for tumour biology: a FISH analysis of four cases on touch imprint smears.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 22 / genetics. Ependymoma / genetics
  • [MeSH-minor] Adult. Cytodiagnosis. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • Genetic Alliance. consumer health - Chromosome 22.
  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879268.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR: Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol; 2010 Aug;12(8):862-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience.
  • This study reports on a series of adult patients with confirmed ependymoma treated at The University of Texas M. D.
  • Patients aged >17 and with ependymoma were identified, and clinical data were collected by retrospective chart review.
  • This series included 123 adult patients [51% male; median age 39 years (18-72)].
  • Forty had tumors in the brain, 80 in the spine, and 3 had both.
  • Median time to recurrence was 21 months (Grade II) brain and 18 months (Grade III).
  • Worse outcome measured by overall and progression-free survival were associated with brain location (P = .01, P = .04) and tumor anaplasia (P = .0025, P = .001).
  • Tumor grade and brain location are associated with a worse prognosis.
  • Reclassification of ependymoma by neuropathologists is common.
  • Results of this study have lead to a multicenter study to further define important diagnostic and prognostic variables for adults with ependymoma.
  • [MeSH-major] Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / pathology. Ependymoma / mortality. Ependymoma / pathology. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Proportional Hazards Models. Radiotherapy. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):542-53 [11013626.001]
  • [Cites] J Neurosurg. 2009 Apr;110(4):725-9 [19061350.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1221-9 [15022290.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1457-62 [3624024.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):283-90 [1517804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Pediatr Neurosurg. 1998 Jan;28(1):49-55 [9693331.001]
  • [Cites] Radiographics. 2005 Mar-Apr;25(2):486-90 [15798065.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1):E192; discussion E192 [15987557.001]
  • [Cites] Brain. 2007 May;130(Pt 5):1338-49 [17449478.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):307-16 [18532929.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jan;52(1):65-9 [19006249.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • (PMID = 20511182.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC2940672
  •  go-up   go-down


71. Lindsey JC, Lusher ME, Strathdee G, Brown R, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC: Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer; 2006 Jan 15;118(2):346-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours.
  • We examined the status of MCJ in intracranial primitive neuroectodermal tumours [PNETs, comprising cerebellar PNETs (medulloblastomas) and supratentorial PNETs (stPNETs)] and ependymomas, together representing the most common malignant brain tumours of childhood.
  • Evidence of MCJ hypermethylation was found in all 3 tumour types [medulloblastomas, 3/9 (33%) cell lines, 2/28 (7%) primary tumours; stPNETs, 2/2 (100%) cell lines, 3/10 (30%) primary tumours; and ependymomas, 2/20 (10%) primary tumours] but not in nonneoplastic brain tissues (n = 11), indicating that MCJ methylation is a tumour-specific event.
  • These data indicate that epigenetic inactivation of MCJ may play a role in the development of a range of paediatric brain tumour types, and its role in disease pathogenesis and chemotherapeutic resistance should now be investigated further.
  • [MeSH-major] Brain Neoplasms / genetics. Ependymoma / genetics. Epigenesis, Genetic. HSP40 Heat-Shock Proteins / biosynthesis. Membrane Proteins / biosynthesis. Neuroectodermal Tumors, Primitive / genetics
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Child. Child, Preschool. DNA Methylation. Female. Gene Expression Profiling. Gene Silencing. Humans. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16049974.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNAJC1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Membrane Proteins
  •  go-up   go-down


72. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA: The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol; 2009 Dec;95(3):401-411
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.
  • In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported.
  • The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for the registration of malignant and non-malignant brain tumours.
  • All Austrian neuropathology units involved in brain tumour diagnostics contribute data on primary brain tumours.
  • In 2005, we registered a total of 1,688 newly diagnosed primary brain tumours in a population of 8.2 million inhabitants with an overall age-adjusted incidence rate of 18.1/100,000 person-years.
  • Comparison with the Central Brain Tumor Registry of the United States (CBTRUS) database showed high congruency of findings.
  • The ABTR model led by neuropathologists in collaboration with epidemiologists and the Austrian National Cancer Registry presents a cooperative way to establish a population-based brain tumour registry with high quality data.
  • The continued operation of ABTR will aid in monitoring changes in incidence and in identifying regional disease clusters or geographic variations in brain tumour morbidity/mortality.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Registries / standards. Registries / statistics & numerical data
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Austria / epidemiology. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Female. Geographic Information Systems. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Middle Aged. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Reproducibility of Results. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562257.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M, Yamasaki M: D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol; 2006 Jul;19(7):974-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells.
  • Some brain tumors such as anaplastic ependymoma, some medulloblastomas, glioblastoma, pineal germinoma, craniopharyngioma, choroid plexus papilloma, choroid plexus carcinoma, and meningioma showed positive immunoreactivity with D2-40.
  • Therefore, D2-40 antibody is considered a useful marker for research on developing brain and diagnosis of brain tumors, differentiation between choroid plexus carcinoma and metastatic carcinoma.
  • [MeSH-major] Antibodies, Monoclonal. Antigens, Neoplasm / analysis. Brain Neoplasms / immunology. Cerebellum / immunology. Telencephalon / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation. Cells, Cultured. Child, Preschool. Fetus / immunology. Gestational Age. Humans. Immunohistochemistry. Infant. Middle Aged. Neurons / cytology. Neurons / immunology. Prosencephalon / cytology. Stem Cells / cytology. Stem Cells / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648867.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


74. Lasky JL 3rd, Choe M, Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther; 2009 Dec;4(4):298-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells in pediatric brain tumors.
  • Although recent studies have focused on molecular mechanisms that underlie the initiation and progression of adult glioblastoma multiforme (GBM), these tumors differ phenotypically and at a molecular level from pediatric brain tumors.
  • Recent investigations have identified a stem cell population, termed "brain tumor stem cells" (BTSC) within the heterogeneous cell populations that comprise malignant brain tumors which may be partly responsible for the resistance to current therapies.
  • By exploiting molecular differences present within these heterogeneous populations of brain tumor cells, we may be able to achieve specific eradication of BTSC and long-lasting remissions, while causing less toxicity to normal tissues.
  • In this review, we describe the issues surrounding the identification and characterization of BTSC, the molecular biology of BTSC for different pediatric brain tumors, and suggest future avenues for the development of treatments for this devastating disease.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Medulloblastoma / pathology. Neoplastic Stem Cells / pathology. Optic Nerve Glioma / pathology
  • [MeSH-minor] Adult Stem Cells / pathology. Biomarkers / metabolism. Cell Differentiation. Chemotherapy, Adjuvant. Child. Humans. Surgical Procedures, Operative


75. Lehman NL: Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors. J Neuropathol Exp Neurol; 2008 Sep;67(9):900-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors.
  • Ependymomas are generally considered to be noninfiltrative tumors that have discrete borders with adjacent brain tissue.
  • The 3 cortical ependymal tumors show a spectrum of features ranging from conventional and clear-cell ependymoma-like patterns to more angiocentric glioma-like histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2000 Mar;16(3):170-5 [10804053.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Mar;67(3):177-88 [18344909.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Pediatr Neurosurg. 2003 Jul;39(1):50-4 [12784079.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):357-62 [12898154.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):914-20 [15223962.001]
  • [Cites] J Neuropathol Exp Neurol. 1978 Mar-Apr;37(2):103-18 [632843.001]
  • [Cites] Int Rev Cytol. 1985;96:121-55 [2416706.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):67-74 [7709787.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] No Shinkei Geka. 1999 Sep;27(9):843-6 [10478346.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1):E192; discussion E192 [15987557.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Oct;64(10):875-81 [16215459.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):281-6 [16389940.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):388-95 [16342252.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):313-24 [17061076.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1709-18 [18059228.001]
  • [Cites] Neuropathology. 2008 Feb;28(1):81-6 [18021197.001]
  • [Cites] Pediatr Neurosurg. 2001 Feb;34(2):77-87 [11287807.001]
  • (PMID = 18716554.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS045077; United States / NINDS NIH HHS / NS / NS045077-05; United States / NINDS NIH HHS / NS / K08 NS045077-05; United States / NINDS NIH HHS / NS / K08 NS45077
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS131630; NLM/ PMC2805172
  •  go-up   go-down


76. Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Jouvet A, Guyotat J: [Intracranial ependymomas in adult patients. Retrospective analysis of 121 cases from the multicentric French study]. Neurochirurgie; 2007 Jun;53(2-3 Pt 1):66-75
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial ependymomas in adult patients. Retrospective analysis of 121 cases from the multicentric French study].
  • We report a retrospective study of 121 cases intracranial ependymomas diagnosed between 1990 and 2004 in adult patients.
  • This study demonstrated that extent of surgery and tumor grade are the two main prognostic factors in adult intracranial ependymomas with respect to overall and progression-free survival.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neurosurgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475290.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


77. Maranhão ET, Maranhão-Filho P, Lima MA, Vincent MB: Can clinical tests detect early signs of monohemispheric brain tumors? J Neurol Phys Ther; 2010 Sep;34(3):145-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can clinical tests detect early signs of monohemispheric brain tumors?
  • The purpose of this study was to determine the sensitivity and specificity of 13 clinical tests for detection of subtle motor deficits in patients with unilateral brain tumors.
  • METHODS: Sixty patients with unilateral brain tumors without obvious focal signs and 30 controls with normal magnetic resonance imaging were examined.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Neurologic Examination / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Early Diagnosis. Ependymoma / diagnosis. Female. Functional Laterality. Humans. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Middle Aged. Neurocytoma / diagnosis. Predictive Value of Tests. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799429.001).
  • [ISSN] 1557-0584
  • [Journal-full-title] Journal of neurologic physical therapy : JNPT
  • [ISO-abbreviation] J Neurol Phys Ther
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Puputti M, Tynninen O, Pernilä P, Salmi M, Jalkanen S, Paetau A, Sihto H, Joensuu H: Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors. Brain Pathol; 2010 Jul;20(4):763-70
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors.
  • KIT receptor tyrosine kinase is expressed in tumor endothelial cells of adult glioblastomas, but its expression in pediatric brain tumor endothelial cells is unknown.
  • We assessed expression of KIT, phosphorylated KIT, stem cell factor (SCF) and vascular endothelial growth factor receptor-2 (VEGFR-2) in 35 juvenile pilocytic astrocytomas and 49 other pediatric brain tumors using immunohistochemistry, and KIT messenger RNA (mRNA) using in situ hybridization.
  • KIT and phospho-KIT were present in endothelia of other pediatric brain tumors, notably ependymomas.
  • Endothelial cell KIT expression was associated with a young age at diagnosis of pilocytic astrocytoma or ependymoma, and it was occasionally present in histologically normal tissue of the fetus and children.
  • We conclude that KIT is commonly present in endothelial cells of juvenile brain tumors and thus may play a role in angiogenesis in these neoplasms.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Endothelial Cells / metabolism. Ependymoma / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Humans. Immunohistochemistry. In Situ Hybridization. Infant. Infant, Newborn. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Statistics, Nonparametric. Vascular Endothelial Growth Factor Receptor-2 / genetics. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 May;13(5):536-41 [10824925.001]
  • [Cites] Histopathology. 2009 Nov;55(5):544-53 [19912360.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7674-8 [14633689.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18600-7 [14985355.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2397-401 [15150569.001]
  • [Cites] J Comp Neurol. 2004 Jul 19;475(2):247-60 [15211465.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Cell. 1990 Oct 5;63(1):225-33 [1698557.001]
  • [Cites] Cell. 1990 Oct 5;63(1):235-43 [1698558.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):667-9 [1699134.001]
  • [Cites] Development. 1991 Dec;113(4):1207-21 [1811937.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Sep;51(5):488-92 [1381413.001]
  • [Cites] Trends Genet. 1993 Aug;9(8):285-90 [7691001.001]
  • [Cites] Development. 1993 Sep;119(1):49-56 [7506140.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 May;54(3):304-10 [7745429.001]
  • [Cites] Brain Res Dev Brain Res. 1995 Apr 18;85(2):201-11 [7541320.001]
  • [Cites] Pediatr Dev Pathol. 2004 Sep-Oct;7(5):493-8 [15547773.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] J Pathol. 2005 Oct;207(2):224-31 [16021678.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1415-22 [16818499.001]
  • [Cites] J Pathol. 2007 Mar;211(4):481-8 [17294421.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1853-61 [18339685.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1467-72 [11073807.001]
  • (PMID = 20030644.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2901521
  •  go-up   go-down


79. Bonner MJ, Hardy KK, Willard VW, Anthony KK, Hood M, Gururangan S: Social functioning and facial expression recognition in survivors of pediatric brain tumors. J Pediatr Psychol; 2008 Nov-Dec;33(10):1142-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Social functioning and facial expression recognition in survivors of pediatric brain tumors.
  • OBJECTIVE: To assess social functioning and facial expression recognition skill in survivors of pediatric brain tumors (BT) as compared to children with juvenile rheumatoid arthritis (JRA).
  • RESULTS: After controlling for estimated IQ, survivors of BT made significantly more errors interpreting adult facial expressions as compared to children with JRA.
  • [MeSH-major] Brain Damage, Chronic / psychology. Brain Neoplasms / psychology. Cognition Disorders / psychology. Emotions. Facial Expression. Pattern Recognition, Visual. Socialization. Survivors / psychology
  • [MeSH-minor] Adolescent. Arthritis, Juvenile / psychology. Astrocytoma / psychology. Cerebellar Neoplasms / psychology. Child. Ependymoma / psychology. Female. Humans. Intelligence. Male. Medulloblastoma / psychology. Personal Construct Theory. Social Behavior Disorders / diagnosis. Social Behavior Disorders / psychology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18390896.001).
  • [ISSN] 1465-735X
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Bouffet E, Tabori U, Huang A, Bartels U: Ependymoma: lessons from the past, prospects for the future. Childs Nerv Syst; 2009 Nov;25(11):1383-4; author reply 1385
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma: lessons from the past, prospects for the future.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Brain Neoplasms / therapy. Child. Child, Preschool. Humans. Practice Guidelines as Topic. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery. Spinal Neoplasms / therapy. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Childs Nerv Syst. 2009 Mar;25(3):281-4 [19153750.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):675-89 [18701711.001]
  • [Cites] Lancet Oncol. 2007 Aug;8(8):696-705 [17644039.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1129-35 [18797459.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1522-8 [16575002.001]
  • [Cites] Pediatr Neurol. 1996 Apr;14(3):216-19 [8736405.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):258-66 [19274783.001]
  • [Cites] J Neurosurg. 1983 Oct;59(4):652-9 [6886786.001]
  • [Cites] Childs Nerv Syst. 2009 Mar;25(3):281-4 [19153750.001]
  • [Cites] Pediatr Neurosurg. 1998 Jul;29(1):40-5 [9755311.001]
  • (PMID = 19562351.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  •  go-up   go-down


81. Barresi V, Tuccari G, Barresi G: NGAL immunohistochemical expression in brain primary and metastatic tumors. Clin Neuropathol; 2010 Sep-Oct;29(5):317-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NGAL immunohistochemical expression in brain primary and metastatic tumors.
  • Thus NGAL urinary detection has been proposed as a method for the early diagnosis of brain tumors.
  • In view of this, the objective of this study was to investigate whether NGAL expression differs according to brain tumor type or in primary vs. metastatic brain neolasias.
  • 42 surgically resected formalin fixed and paraffin embedded neoplasias, including 15 cases of brain metastasis and 27 cases of primary central nervous system (CNS) tumors (11 meningiomas; 1 pilocytic astrocytoma, 2 diffuse astrocytomas, 2 oligoastrocytomas, 2 oligodendrogliomas, 1 anaplastic oligoastrocytoma, 7 glioblastomas, 1 ependymoma) were submitted to the immunohistochemical procedure.
  • In conclusion, our findings suggest that NGAL expression is restricted to high grade gliomas among primary brain tumors, and that brain metastases do not express this protein.
  • Considering the correlation between NGAL expression in tumors and its urinary levels, if our observations will be further validated, NGAL urinary detection might be used as an additional tool in the pre-surgical definition of brain lesions involving difficult differential diagnosis.
  • [MeSH-major] Acute-Phase Proteins / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / secondary. Lipocalins / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860895.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


82. Kalapurakal JA, Goldman S, Stellpflug W, Curran J, Sathiaseelan V, Marymont MH, Tomita T: Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):800-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy).
  • PURPOSE: To describe the preliminary results after intraoperative radiotherapy (IORT) with the photon radiosurgery system in children with recurrent brain tumors treated at the first dose level (10 Gy) of a Phase I protocol.
  • METHODS AND MATERIALS: A Phase I IORT dose escalation protocol was initiated at Children's Memorial Hospital to determine the maximal tolerated IORT dose in children with recurrent brain tumors.
  • Thirteen children had ependymoma.
  • CONCLUSION: Our findings have demonstrated the safety and feasibility of IORT to a dose of 10 Gy to 2 mm in children with previously irradiated brain tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Photons / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Brain / pathology. Brain / radiation effects. Child. Ependymoma / radiotherapy. Ependymoma / surgery. Feasibility Studies. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Humans. Intraoperative Period. Male. Maximum Tolerated Dose. Necrosis / etiology. Radiation Injuries / etiology. Radiosurgery / instrumentation. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580791.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Ishizawa K, Komori T, Shimada S, Hirose T: Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol; 2008 May-Jun;27(3):118-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
  • A total of 59 brain tumors including 16 ependymomas, 32 astrocytomas, and 11 oligodendrogliomas were immunohistochemically studied for the expression of Olig2 as well as other markers including epithelial membrane antigen (EMA) and CD99.
  • Particularly in cases of glioblastoma or pilocytic astrocytoma that histologically mimicked ependymoma, the Olig2-positive nuclei were numerous as in conventional astrocytomas, which helped to differentiate them from ependymomas.
  • The EMA-positive structures were helpful for the diagnosis of ependymoma, however, they were occasionally very modest and sparse on immunostained sections.
  • In our preliminary experiment, we noted the absence of CD99-immunoreactivity in a fraction of brain tumors with clear cell morphology, including oligodendroglioma, clear cell ependymoma, and pilocytic astrocytoma (the oligodendroglioma-like component).
  • Thus, we investigated the expression of CD99 in an additional series of brain tumors with clear cell morphology, including oligoastrocytoma (7 cases), central neurocytoma (6), and dysembryoplastic neuroepithelial tumor (9).
  • The CD99-immunohistochemistry is unique in that it is helpful for the diagnosis of clear cell brain tumors through the visualization of CD99-negative clear cells.
  • [MeSH-major] Antigens, CD / genetics. Antigens, CD / metabolism. Basic Helix-Loop-Helix Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Cell Nucleus / chemistry. Child. Child, Preschool. Diagnosis, Computer-Assisted. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mucin-1 / analysis. Phenotype

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552083.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


84. Majós C, Aguilera C, Cos M, Camins A, Candiota AP, Delgado-Goñi T, Samitier A, Castañer S, Sánchez JJ, Mato D, Acebes JJ, Arús C: In vivo proton magnetic resonance spectroscopy of intraventricular tumours of the brain. Eur Radiol; 2009 Aug;19(8):2049-59

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo proton magnetic resonance spectroscopy of intraventricular tumours of the brain.
  • Characteristic trends were found for some groups: high Glx and Ala in meningiomas (p < 0.001 and p < 0.01, respectively), high mobile lipids in metastasis (p < 0.001), high Cho in PNET (p < 0.001), high mI + Gly in ependymoma (p < 0.001), high NAC (p < 0.01) in the absence of the normal brain parenchyma pattern in colloid cysts, and high mI/Gly and Ala in central neurocytoma.
  • Proton MR spectroscopy provides additional metabolic information that could be useful in the diagnosis of intraventricular brain tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain / metabolism. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Protons. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):84-93 [10669230.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):55-60 [11147898.001]
  • [Cites] Magn Reson Med. 2003 Oct;50(4):697-703 [14523954.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):683-8 [16163043.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Radiology. 2005 Sep;236(3):1020-5 [16118174.001]
  • [Cites] Radiology. 2007 May;243(2):539-50 [17456876.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):560-72 [16551993.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] MAGMA. 2004 Sep;17(1):36-46 [15340855.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Neuroradiology. 2003 Mar;45(3):129-36 [12684713.001]
  • [Cites] Magn Reson Med. 1991 Sep;21(1):82-96 [1682784.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1593-603 [7502961.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] NMR Biomed. 1998 Jun-Aug;11(4-5):177-91 [9719572.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Oct;16(9):1821-33 [8693982.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):78-82 [11436218.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E4 [16048290.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 May;11(3):567-74 [2349896.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):411-34 [16763971.001]
  • [Cites] Radiology. 2002 Nov;225(2):556-66 [12409595.001]
  • (PMID = 19277673.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


85. Barnholtz-Sloan JS, Severson RK, Stanton B, Hamre M, Sloan AE: Pediatric brain tumors in non-Hispanics, Hispanics, African Americans and Asians: differences in survival after diagnosis. Cancer Causes Control; 2005 Jun;16(5):587-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric brain tumors in non-Hispanics, Hispanics, African Americans and Asians: differences in survival after diagnosis.
  • BACKGROUND: Racial differences in survival for children with brain tumors have not been well studied, particularly in Hispanics and Asians.
  • The objective of this study was to assess racial differences in survival of children with brain tumors, focusing on Hispanics, African Americans and Asians compared to Non-Hispanics.
  • METHODS: Subjects identified through the SEER Program were 2799 children, < or =19 years old at diagnosis, newly diagnosed between 1973 and 1996 with primary, malignant brain tumors.
  • [MeSH-major] Brain Neoplasms / mortality. Continental Population Groups / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / ethnology. Astrocytoma / mortality. Astrocytoma / therapy. Child. Child, Preschool. Ependymoma / ethnology. Ependymoma / mortality. Ependymoma / therapy. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / ethnology. Medulloblastoma / mortality. Medulloblastoma / therapy. Proportional Hazards Models. SEER Program. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986114.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


86. Guyotat J, Metellus P, Giorgi R, Barrie M, Jouvet A, Fevre-Montange M, Chinot O, Durand A, Figarella-Branger D: Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir (Wien); 2009 Aug;151(8):947-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients.
  • OBJECT: This study was undertaken to analyze outcomes and to assess the prognostic impact of age, location, surgery, radiotherapy (RT), and histopathology in a series of adult infratentorial ependymomas.
  • METHODS: This was a retrospective study of a population of 106 adult patients with infratentorial ependymomas diagnosed between 1990 and 2004.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Stem / surgery. Cerebellum / surgery. Ependymoma / surgery. Infratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Neurosurgical Procedures / methods. Neurosurgical Procedures / mortality. Neurosurgical Procedures / statistics & numerical data. Outcome Assessment (Health Care) / methods. Postoperative Complications / epidemiology. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499166.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


87. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH: Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res; 2007 Feb 1;67(3):890-900
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.
  • Lastly, we also identified a gene expression pattern common to PAs and normal mouse astrocytes and neural stem cells from these distinct brain regions as well as a gene expression pattern shared between PAs and another human glial tumor (ependymoma) arising supratentorially compared with those originating in the posterior fossa.
  • These results suggest that glial tumors share an intrinsic, lineage-specific molecular signature that reflects the brain region in which their nonmalignant predecessors originated.
  • [MeSH-minor] Adolescent. Adult. Algorithms. Child. Child, Preschool. Cluster Analysis. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / metabolism. Neurofibromatosis 1 / pathology. Oligonucleotide Array Sequence Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283119.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE5582/ GSE5675
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Souweidane MM, Morgenstern PF, Christos PJ, Edgar MA, Khakoo Y, Rutka JT, Dunkel IJ: Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors. Neurosurgery; 2009 Jul;65(1):72-8; discussion 78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors.
  • OBJECTIVE: This study was conducted to determine whether arachnoid tissue or cerebrospinal fluid (CSF) sampling is valuable for risk stratification in children with posterior fossa brain tumors.
  • Arachnoid infiltration and CSF cytology were found in 20.0% and 44.8%, respectively, for medulloblastoma/pineoblastoma (primitive neuroectodermal tumor), 6.9% and 3.6% for pilocytic astrocytoma, and 0.0% and 33.3% for ependymoma.
  • CONCLUSION: Intraoperative evidence of arachnoid infiltration or CSFCM dissemination in patients with posterior fossa brain tumors occurs at a variable frequency that is dependent on tumor type, correlates with conventional M stage, and may be predictive of outcome.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574827.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Goldhoff P, Warrington NM, Limbrick DD Jr, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB: Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res; 2008 Dec 1;14(23):7717-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
  • PURPOSE: As favorable outcomes from malignant brain tumors remain limited by poor survival and treatment-related toxicity, novel approaches to cure are essential.
  • Here, we investigate the role of PDE4 in brain tumors and examine the utility of PDE4 as a therapeutic target.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was used to evaluate the expression pattern of a subfamily of PDE4, PDE4A, in multiple brain tumor types.
  • To evaluate the effect of PDE4A on growth, a brain-specific isoform, PDE4A1 was overexpressed in xenografts of Daoy medulloblastoma and U87 glioblastoma cells.
  • RESULTS: We found that PDE4A is expressed in medulloblastoma, glioblastoma, oligodendroglioma, ependymoma, and meningioma.
  • CONCLUSIONS: This study shows that PDE4 is widely expressed in brain tumors and promotes their growth and that inhibition with Rolipram overcomes tumor resistance and mediates tumor regression.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11392-9 [16357147.001]
  • [Cites] Drug Discov Today. 2005 Nov 15;10(22):1503-19 [16257373.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1666-78 [16478988.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):733-54 [16759164.001]
  • [Cites] Biochem Soc Trans. 2006 Aug;34(Pt 4):504-9 [16856845.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3799-810 [16940352.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] Curr Top Dev Biol. 2006;75:225-59 [16984814.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):651-8 [17234775.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5248-57 [17545604.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Chem Res Toxicol. 2000 Oct;13(10):944-8 [11080038.001]
  • [Cites] Cell Signal. 2001 Dec;13(12):911-8 [11728831.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28298-309 [11994273.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):268-76 [12432276.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] J Neurosurg. 1977 Apr;46(4):477-83 [191576.001]
  • [Cites] J Neurooncol. 1983;1(1):61-7 [6086852.001]
  • [Cites] Pharmacopsychiatry. 1984 Nov;17(6):188-90 [6393150.001]
  • [Cites] Biochem J. 1993 Jun 15;292 ( Pt 3):677-86 [7686364.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3058-61 [8391385.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):673-81 [7772057.001]
  • [Cites] Eur J Cancer. 1995;31A(5):714-7 [7640043.001]
  • [Cites] Biochem J. 1995 Sep 15;310 ( Pt 3):965-74 [7575434.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):161-8 [9120546.001]
  • [Cites] Neurosci Lett. 1998 Mar 6;244(1):41-6 [9578140.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):693-703 [9677330.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4733-43 [9822544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] Cell Signal. 2005 Sep;17(9):1158-73 [15905070.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1523-31 [16034090.001]
  • [Cites] Arch Toxicol. 2006 Feb;80(2):88-97 [16167140.001]
  • [Cites] Nat Methods. 2005 Aug;2(8):607-14 [16094386.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33178-89 [16030021.001]
  • [CommentIn] Clin Cancer Res. 2009 May 1;15(9):3238; author reply 3238-9 [19406836.001]
  • (PMID = 19047098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NINDS NIH HHS / NS / P30 NS057105; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R21 CA108677; United States / NCI NIH HHS / CA / P50 CA94056; United States / NCI NIH HHS / CA / P50 CA094056-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phosphodiesterase Inhibitors; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; K676NL63N7 / Rolipram
  • [Other-IDs] NLM/ NIHMS82831; NLM/ PMC2615415
  •  go-up   go-down


90. Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, Jouvet A, Guyotat J: Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain; 2007 May;130(Pt 5):1338-49
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients.
  • The authors report a retrospective study of a homogenous population of 152 adult patients harbouring intracranial ependymomas from 24 French Neurosurgical Centres between 1990 and 2004.
  • In association with Karnofski performance status and extent of surgery, histological grade is a major prognostic factor in adult intracranial ependymomas.
  • [MeSH-major] Brain Neoplasms / mortality. Ependymoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. France. Humans. Karnofsky Performance Status. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449478.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Oner AY, Celik H, Tali T, Akpek S, Tokgoz N: Thin-section diffusion-weighted magnetic resonance imaging of the brain with parallel imaging. Acta Radiol; 2007 May;48(4):456-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thin-section diffusion-weighted magnetic resonance imaging of the brain with parallel imaging.
  • When a brain lesion was present, contrast-to-noise ratio (CNR) and corresponding ADC were also measured.
  • RESULTS: Mean SNR values of the normal brain were 33.61+/-4.35 and 32.98+/-7.19 for conventional and thin-slice DWI (P>0.05), respectively.
  • Mean ADCs of the brain obtained by both techniques were comparable (P>0.05).
  • [MeSH-major] Brain Diseases / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Image Processing, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Brain / anatomy & histology. Brain Infarction / diagnosis. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Echo-Planar Imaging / methods. Ependymoma / diagnosis. Female. Glioblastoma / diagnosis. Humans. Image Enhancement / methods. Male. Middle Aged. Prospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453529.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


92. Neuwelt EA, Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig GW, Muldoon LL: Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer; 2006 Aug;47(2):174-82
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
  • PURPOSE: To assess the safety of delayed high dose intravenous (i.v.) sodium thiosulfate (STS) in a case series of 12 children with malignant brain tumors who were treated with intraarterial (i.a.) carboplatin in conjunction with blood-brain-barrier disruption (BBBD).
  • Analogous to results in adult patients, there was mild transient hypernatremia and a trend for improved protection from ototoxicity in children who received STS delayed to 4 hr post-treatment versus 2 hr.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Brain Neoplasms / drug therapy. Carboplatin / adverse effects. Chelating Agents / administration & dosage. Hearing Loss, Sensorineural / prevention & control. Thiosulfates / administration & dosage
  • [MeSH-minor] Auditory Threshold. Blood-Brain Barrier. Child. Child, Preschool. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Ependymoma / drug therapy. Ependymoma / pathology. Female. Humans. Infant. Infusions, Intravenous. Male. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Aug;47(2):120-2 [16206212.001]
  • (PMID = 16086410.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chelating Agents; 0 / Thiosulfates; BG3F62OND5 / Carboplatin; HX1032V43M / sodium thiosulfate
  •  go-up   go-down


93. Liu JG, Liu YH, Cai J, Liu XS, Song WZ, Huang Y, Mao Q: [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):868-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors].
  • OBJECTIVE: To detect and analysis epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in different malignancy brain tumors, and to evaluate their prognostic significance.
  • However amplification of EGFR and deletion of PTEN were relatively low in other malignancy brain tumors.
  • PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma, so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236582.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


94. Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, Jouvet A, Figarella-Branger D: Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol; 2010 Sep;12(9):976-84
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.
  • The authors report a retrospective study of a homogenous population of 114 adult patients harboring WHO grade II intracranial ependymomas from 32 French Neurosurgical Centers between 1990 and 2004.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Ependymoma / mortality. Ependymoma / pathology. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Radiotherapy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):387-91 [15667957.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):629-36 [15871504.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):605-13 [11014538.001]
  • [Cites] Surg Neurol. 2000 Jul;54(1):19-26; discussion 26 [11024503.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):117-22 [11943886.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):255-68 [12510777.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1221-9 [15022290.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] Surg Neurol. 1988 Apr;29(4):271-81 [3353839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):313-9 [1587752.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):807-22 [9161731.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):3-10 [9364625.001]
  • [Cites] Br J Neurosurg. 1997 Oct;11(5):421-8 [9474274.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Cancer. 2009 Sep 1;115(17):3955-68 [19536879.001]
  • [Cites] J Surg Res. 2009 Oct;156(2):340-51 [19577759.001]
  • [Cites] J Neurosurg. 2005 Jul;103(1):31-7 [16121970.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):388-95 [16342252.001]
  • [Cites] Brain. 2007 May;130(Pt 5):1338-49 [17449478.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):585-9 [10837939.001]
  • (PMID = 20484442.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940702
  •  go-up   go-down


95. Song JH, Kong DS, Shin HJ: Feasibility of neuroendoscopic biopsy of pediatric brain tumors. Childs Nerv Syst; 2010 Nov;26(11):1593-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of neuroendoscopic biopsy of pediatric brain tumors.
  • RESULTS: In 45 of 49 patients (91.8%) neuroendoscopic biopsy specimens were appropriate for diagnosis and revealed 27 germinomas, 11 astrocytomas, and one ependymoma, etc.
  • [MeSH-major] Biopsy / methods. Brain Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Hypothalamic Neoplasms / pathology. Neuroendoscopy / methods. Pinealoma / pathology. Thalamic Diseases / pathology
  • [MeSH-minor] Adolescent. Cerebral Ventricles / pathology. Child. Child, Preschool. Feasibility Studies. Female. Humans. Hypothalamus / pathology. Infant. Male. Pineal Gland / pathology. Postoperative Complications / etiology. Thalamus / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1978 Mar-Apr;2(2):110-3 [732959.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Mar;40(1):13-5; discussion 16 [9138302.001]
  • [Cites] J Neurosurg. 1973 Feb;38(2):251-6 [4694225.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):880-9 [12234394.001]
  • [Cites] Br J Neurosurg. 2002 Oct;16(5):465-70 [12498490.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):93-5 [12046745.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3 Suppl):219-26 [16970236.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):791-7 [11702869.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurosurg. 2004 May;100(5 Suppl Pediatrics):437-41 [15287451.001]
  • [Cites] Ann Surg. 1933 Nov;98(5):841-5 [17867081.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Jun;44(2):70-3 [11487787.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):267-77; discussion 267-77 [16883167.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):496-505 [9488304.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):277-86 [11767293.001]
  • [Cites] Childs Nerv Syst. 1999 Apr;15(4):179-84 [10361968.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):271-8 [17219833.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1235-9 [19002372.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Oct;46(5):293-9 [14628246.001]
  • [Cites] J Neurosurg. 2005 Nov;103(5 Suppl):393-400 [16302610.001]
  • [Cites] Neurosurg Focus. 1999 Apr 15;6(4):e14 [16681354.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):269-72 [12527921.001]
  • (PMID = 20390421.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Weber M, Stadlbauer A, Grabner G, Knosp E, Trattnig S: High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology; 2008 Jan;50(1):9-16
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors.
  • INTRODUCTION: To demonstrate intratumoral susceptibility effects in malignant brain tumors and to assess visualization of susceptibility effects before and after administration of the paramagnetic contrast agent MultiHance (gadobenate dimeglumine; Bracco Imaging), an agent known to have high relaxivity, with respect to susceptibility effects, image quality, and reduction of scan time.
  • METHODS: Included in the study were 19 patients with malignant brain tumors who underwent high-resolution, susceptibility-weighted (SW) MR imaging at 3 T before and after administration of contrast agent.
  • [MeSH-major] Brain Neoplasms / diagnosis. Contrast Media / administration & dosage. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Meglumine / analogs & derivatives. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Brain / pathology. Efficiency. Ependymoma / diagnosis. Female. Glioblastoma / diagnosis. Humans. Male. Middle Aged. Oligodendroglioma / diagnosis. Plasmacytoma / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2006 Jul;24(1):41-51 [16755540.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):439-50 [16163700.001]
  • [Cites] Neuroradiology. 2001 May;43(5):364-9 [11396739.001]
  • [Cites] NMR Biomed. 2001 Nov-Dec;14(7-8):453-67 [11746938.001]
  • [Cites] Invest Radiol. 2003 Jul;38(7):409-14 [12821854.001]
  • [Cites] Invest Radiol. 1999 Jun;34(6):427-34 [10353036.001]
  • [Cites] MAGMA. 1998 Aug;6(1):62-9 [9794291.001]
  • [Cites] Invest Radiol. 2002 Mar;37(3):114-9 [11882790.001]
  • [Cites] Radiology. 1997 Feb;202(2):511-6 [9015082.001]
  • [Cites] Invest Radiol. 2006 Mar;41(3):249-55 [16481907.001]
  • [Cites] J Comput Assist Tomogr. 2000 Nov-Dec;24(6):949-57 [11105717.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):118-23 [10441013.001]
  • (PMID = 17876570.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


97. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM: Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res; 2006 Mar 1;12(5):1540-6
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
  • PURPOSE: A phase I trial of intrathecal Spartaject Busulfan (SuperGen, Inc., San Ramon, CA) was conducted in children with neoplastic meningitis following recurrent primary brain tumors to describe toxicities, estimate the maximum tolerated dose (MTD), and document evidence of responses to this agent.
  • CONCLUSIONS: Intrathecal Spartaject Busulfan was well tolerated in children with neoplastic meningitis from brain tumors, and the recommended dose for future phase II studies is 13 mg.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Choroid Plexus Neoplasms / blood. Choroid Plexus Neoplasms / cerebrospinal fluid. Choroid Plexus Neoplasms / drug therapy. Cohort Studies. Ependymoma / blood. Ependymoma / cerebrospinal fluid. Ependymoma / drug therapy. Female. Glioma / blood. Glioma / cerebrospinal fluid. Glioma / drug therapy. Humans. Injections, Spinal. Male. Maximum Tolerated Dose. Neuroectodermal Tumors, Primitive / blood. Neuroectodermal Tumors, Primitive / cerebrospinal fluid. Neuroectodermal Tumors, Primitive / drug therapy

  • MedlinePlus Health Information. consumer health - Meningitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533779.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U01 CA081457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan
  •  go-up   go-down


98. Gonçalves MI, Radzinsky TC, da Silva NS, Chiari BM, Consonni D: Speech-language and hearing complaints of children and adolescents with brain tumors. Pediatr Blood Cancer; 2008 Mar;50(3):706-8
MedlinePlus Health Information. consumer health - Speech and Language Problems in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Speech-language and hearing complaints of children and adolescents with brain tumors.
  • [MeSH-major] Brain Neoplasms / complications. Hearing Loss / etiology. Language Disorders / etiology. Speech Disorders / etiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Astrocytoma / complications. Astrocytoma / drug therapy. Child. Child, Preschool. Craniopharyngioma / complications. Craniopharyngioma / drug therapy. Deglutition Disorders / etiology. Ependymoma / complications. Ependymoma / drug therapy. Facial Paralysis / etiology. Female. Humans. Infant. Male. Medulloblastoma / complications. Medulloblastoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Speech and Communication Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534932.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


99. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol; 2006 Sep;58(3):343-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
  • BACKGROUND: [corrected] Lobradimil is a synthetic bradykinin analog that rapidly and transiently increases the permeability of the blood-brain barrier (BBB).
  • The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression.
  • PATIENTS AND METHODS: Patients were stratified by histology into five cohorts: brainstem glioma, high-grade glioma, low-grade glioma, medullobastoma/primitive neuroectodermal tumor (PNET), and ependymoma.
  • The study was closed for commercial reasons prior to achieving the accrual goals for the ependymoma (n = 8), medulloblastoma/PNET (n = 6) and low-grade glioma (n = 2) cohorts, although responses were observed in 1 patient with PNET and 2 patients with ependymoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / metabolism. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bradykinin / administration & dosage. Bradykinin / adverse effects. Bradykinin / analogs & derivatives. Bradykinin / therapeutic use. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Cohort Studies. Drug Administration Schedule. Humans. Infusions, Intravenous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408203.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down


100. Müller-Forell W: [Neuroradiology of the intracranial visual pathway. Part II]. Radiologe; 2005 Nov;45(11):1043-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Part 2 mainly presents intrinsic lesions as the most common brain tumors (astrocytoma of all grades, ependymoma), arising in the region of the visual pathway.
  • [MeSH-major] Brain Diseases / diagnosis. Magnetic Resonance Imaging. Visual Pathways
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Child. Ependymoma / diagnosis. Female. Hemangioma, Cavernous / diagnosis. Humans. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Middle Aged. Multiple Sclerosis / diagnosis. Sarcoidosis / diagnosis. Sturge-Weber Syndrome / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Radiol. 2004 Feb;49(2):143-78 [14746935.001]
  • [Cites] Kidney Blood Press Res. 2004;27(4):226-38 [15273425.001]
  • [Cites] Surv Ophthalmol. 1994 Mar-Apr;38(5):427-52 [8009427.001]
  • [Cites] Eur J Radiol. 2004 Jan;49(1):31-63 [14975493.001]
  • [Cites] Radiologe. 2000 Nov;40(11):1090-7 [11147324.001]
  • (PMID = 16228165.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 17
  •  go-up   go-down






Advertisement